Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia-inducible factor 2(alpha) inhibitors
Tetrahydro-1H-cyclopenta[cd]indene derivatives are developed to selectively inhibit HIF-2α, addressing the need for effective treatments in diseases like renal cancer and inflammatory bowel disease by reducing HIF-2α activity and improving iron homeostasis.
Patent Information
- Application Number
- JP2021561778
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-12-10
- Filing Date
- 2020-04-16
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-04-16
AI Technical Summary
Current treatments for diseases associated with hypoxia-inducible factor 2α (HIF-2α), such as cancer, liver diseases, inflammatory diseases, lung diseases, and iron disorders, lack effective small molecules that specifically inhibit HIF-2α activity, leading to inadequate therapeutic outcomes.
Development of tetrahydro-1H-cyclopenta[cd]indene derivatives that act as selective HIF-2α inhibitors, which can be administered alone or in combination with other therapeutic agents to target HIF-2α in various diseases, including renal cancer, glioblastoma, and inflammatory bowel disease.
The tetrahydro-1H-cyclopenta[cd]indene derivatives effectively inhibit HIF-2α activity, providing therapeutic benefits in treating a range of diseases by reducing proliferation, modulating the tumor microenvironment, improving iron homeostasis, and enhancing intestinal barrier integrity.
Smart Images

Figure 0007581236000151 
Figure 0007581236000001 
Figure 0007581236000002
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is an international application claiming the benefit of U.S. Provisional Patent Application No. 62 / 836,019, filed April 18, 2019, and U.S. Provisional Patent Application No. 62 / 946,191, filed December 10, 2019, which are incorporated by reference in their entireties herein.
[0002] The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are hypoxia-inducible factor 2 alpha (HIF-2α) inhibitors and are therefore useful in treating diseases treatable by inhibition of HIF-2α. Pharmaceutical compositions containing such compounds and processes for preparing such compounds are also provided. [Background technology]
[0003] Hypoxia is a key regulator of both physiological and pathological processes, including various types of cancer, liver diseases such as nonalcoholic steatohepatitis (NASH), inflammatory diseases such as inflammatory bowel disease (IBD), lung diseases such as pulmonary arterial hypertension (PAH), and iron-loading disorders.
[0004] Hypoxia is well known to promote cancer progression and is associated with poor patient prognosis and resistance to chemotherapy and radiation treatment. Progress over the past decades in elucidating the molecular mechanisms that allow cells to adapt to chronic oxygen deprivation has led to strong interest in developing drugs that can effectively block tumor hypoxia response pathways. Among the signaling modules involved in hypoxia response that have been explored as therapeutic targets for cancer treatment, HIF-α protein continues to attract interest because it offers the possibility of broadly inhibiting downstream hypoxic effects in both tumors and tumor microenvironment. Thus, direct targeting of HIF-α protein provides an excellent opportunity to attack tumors on multiple fronts (see Keith, et al. Nature Rev. Cancer 12:9-22, 2012).
[0005] Hypoxia-inducible factors (HIF-1α and HIF-2α) are key transcription factors of the hypoxic pathway and therefore serve as attractive targets for therapeutic intervention. The half-life of HIF-α protein is tightly controlled by the oxidative status in the cell. Under normoxic conditions, HIF-specific prolyl hydroxylases (PHDs) hydroxylate specific proline residues on HIF proteins, which are recognized by the tumor suppressor von Hippel-Lindau (VHL). Binding of VHL further recruits an E3 ubiquitin-ligase complex that targets HIF-α proteins for degradation via the proteasome. Under hypoxic conditions, when PHDs are inhibited because they require oxygen to function, HIF-α proteins accumulate and enter the nucleus, where they actively promote gene expression. Furthermore, genetic mutations in the VHL gene that result in loss of VHL function result in constitutively active HIF-α proteins independent of oxygen levels. Upon activation, these transcription factors stimulate the expression of genes that collectively regulate anaerobic metabolism, angiogenesis, cell proliferation, cell survival, extracellular matrix remodeling, pH homeostasis, amino acid and nucleotide metabolism, and genomic instability.
[0006] Both HIF-1α and HIF-2α dimerize with HIF-1β (also called ARNT: aryl hydrocarbon receptor nuclear translocator), and the dimer then binds to the hypoxia response element (HRE) of target genes. Since the expression of HIF-1β is independent of oxygen levels or VHL status, the transcriptional activity of the complex is mainly controlled by the availability of HIF-α protein. HIF-1α and HIF-2α differ in their tissue distribution, sensitivity to hypoxia, timing of activation, and target gene specificity (Hu, et al. Mol. Cell Biol. 23:9361-9374, 2003 and Keith, et al. Nature Rev. Cancer 12:9-22, 2012). HIF-1α mRNA is expressed ubiquitously, whereas HIF-2α mRNA expression is found mainly in kidney fibroblasts, hepatocytes, and intestinal luminal epithelial cells. Except for HIF-2α, which is expressed in macrophages, none of the HIF-α is detected in normal tissues (see Talks, et al. Am. J. Pathol. 157:411-421, 2000). In response to hypoxia, HIF-1α exhibits a transient acute transcriptional response. In contrast, HIF-2α exhibits a more long-term transcriptional effect. Furthermore, HIF-2α has higher transcriptional activity than HIF-1α under moderate hypoxic conditions, such as those encountered in terminal capillaries (see Holmquist-Menge / bier, et al. Cancer Cell 10:413-423, 2006). Some hypoxia-regulated genes are controlled by both HIF-1α and HIF-2α, but certain genes respond only to certain HIF-α proteins. For example, lactate dehydrogenase A (LDHA), phosphoglycerate kinase (PGK), and pyruvate dehydrogenase kinase 1 (PDK1) are largely regulated by HIF-1α, whereas Oct-4 and erythropoietin (EPO) are exclusively regulated by HIF-2α.
[0007] In general, the relative contribution of HIF-α proteins to gene transcription is cell type-specific and disease-specific. Indeed, there are reports supporting HIF-α proteins playing opposing roles in tumorigenesis. One example is the regulation of HIF-α on MYC, a key transcription factor that is frequently overexpressed in human cancers. It has been shown that activation of HIF-2α increases MYC transcriptional activity, while HIF-1α inhibits MYC activity. As a result, in MYC-driven tumors, HIF-2α inhibition reduced proliferation and HIF-1α inhibition increased proliferation (see Gordan, et al. Cancer Cell 11:335-347, 2007 and Koshiji et al. EMBO J. 23:1949-1956, 2004). Therefore, the identification of small molecules that specifically inhibit HIF-2α activity is desirable. Furthermore, HIF-2α has been shown to be a major driver of clear cell renal cell carcinoma (ccRCC) with VHL deficiency and several other pseudohypoxic tumors including, but not limited to, glioblastoma, neuroblastoma, somatostatinoma, leiomyoma / leiomyosarcoma, polycythemia erythrocytosis, and retinal abnormalities, etc. Thus, HIF-2α inhibitors offer therapeutic advantages with limited toxicity over pan-HIF-α inhibitors.
[0008] In addition to its direct role in regulating growth-promoting genes in tumor cells (e.g., ccRCC), HIF-2α also mediates the immunosuppressive effects of hypoxia on the tumor microenvironment. HIF-2α expression has been detected in cells of myeloid lineage, and HIF-2α protein accumulation has been readily detected in various human cancers (see Talks KL, et al. Am J Pathol. 2000; 157(2): 411-421). Overexpression of HIF-2α in tumor-associated macrophages (TAMs) is associated with high-grade human tumors and correlates with poor prognosis. Mechanistically, HIF-2α promotes macrophage polarization into the immunosuppressive M2 phenotype and promotes tumor-associated macrophage migration and infiltration (see Imtiyaz HZ et al. J Clin Invest. 2010; 120(8): 2699-2714). In addition, HIF-2α can indirectly promote additional immunosuppressive pathways (e.g., adenosine and arginase) by regulating the expression of key signaling regulators such as adenosine A2B / A2A receptor and arginase. These data suggest that HIF-2α may be a potential therapeutic target for treating a broader range of inflammatory diseases and cancers, either as a single agent or in combination with other therapeutic agents, such as immunotherapeutic agents.
[0009] Due to the role of HIF-α proteins in regulating physiological responses to changes in oxygen levels, they have been causally implicated in many hypoxia-related pathological processes in addition to cancer. Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disease of the intestine. Normally, the intestine maintains dynamic and rapid fluctuations in cellular oxygen tension, with the tips of the epithelial villi being hypoxic and the bases of the epithelial villi being more oxygenated. Dysregulation of epithelial oxygen tension plays a role in intestinal inflammation and resolution in IBD (see Shah YM, Molecular and Cellular Pediatrics, 2016 Dec;3(1):1). Although HIF-1α and HIF-2α can bind to the same canonical HRE, multiple studies have shown that HIF-1α and HIF-2α regulate different subsets of genes, resulting in contrasting effects on IBD symptoms. HIF-1α in intestinal epithelial cells is widely recognized as a major protective factor in IBD (see Karhausen J,et al.J Clin Invest.2004;114(8):1098-1106;Furuta GT,et al.J Exp Med.2001;193(9):1027-1034). However, activation of HIF-2α contributes to IBD through multiple mechanisms, including directly regulating the number of proinflammatory cytokines such as tumor necrosis factor-α to cause inflammation, and indirectly disrupting the integrity of the intestinal barrier by increasing the turnover of tight junction protein obstruction (see Xue X,et al.Gastroenterology.2013;145(4):831-841;Glover LE,et al.Proc Natl Acad Sci USA.2013;110(49):19820-19825). Therefore, in IBD, HIF-2α inhibitors are expected to suppress chronic activation of HIF-2α to reverse the proinflammatory response and enhance intestinal barrier integrity.
[0010] With the increasing prevalence of obesity and metabolic syndrome, NASH is becoming a common chronic liver disease, and available treatment options are limited. Recent studies have shown a positive correlation between intestinal HIF-2α signaling and hepatotoxicity with body mass index, with further animal model studies supporting the causal nature of this correlation (see Xie C, et al. Nat Med. 2017 Nov; 23(11): 1298-1308). Therefore, targeting intestinal HIF-2α represents a novel therapeutic strategy for NASH.
[0011] PAH is a life-threatening disease with a very poor prognosis. Progressive pulmonary vascular remodeling, characterized by concentric pulmonary artery wall thickening and obstructive intimal lesions, is one of the main causes of increased pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) in patients with PAH (see Aggarwal S, et al. Compr Physiol. 2013 Jul;3(3):1011-34). Recently, HIF-2α has been found to contribute to the process of hypoxic pulmonary vascular remodeling, impaired vascular bed plasticity, and ultimately debilitating PAH (see Andrew S., et al. Proc Natl Acad Sci USA. 2016 Aug 2; 113(31): 8801-8806; Tang H, et al. Am J Physiol Lung Cell Mol Physiol. 2018 Feb 1; 314(2): L256-L275). These studies provide new insights into the role of pulmonary endothelial HIF-2α in regulating pulmonary vascular responses to hypoxia and provide much-needed interventional therapeutic strategies by targeting HIF-2α. Summary of the Invention [Problem to be solved by the invention]
[0012] Iron is an essential nutrient required for oxygen delivery and serves as a cofactor for many important enzymatic and redox reactions. HIF-2α regulates the expression of key genes that contribute to iron absorption, and its disruption leads to impaired iron loading. For example, an elegant study using mice lacking HIF-2α in the intestinal epithelium showed that HIF-2α knockout significantly reduced duodenal levels of Dmt1, Dcytb, and FPN mRNA, all key genes in iron transport and absorption. More importantly, these effects were not counteracted by HIF-1α (see Mastrogiannaki M, et al. J Clin Invest. 2009;119(5):1159-1166). Thus, small molecules targeting HIF-2α have the potential to improve iron homeostasis in patients with iron disorders. Thus, the identification of small molecules that inhibit HIF-2α activity is desirable. The present disclosure meets this and related needs. [Means for solving the problem]
[0013] In a first embodiment, the compound of formula (IA): [ka] (In the formula, X 1 is CH or N; R 1 are hydroxy, halo, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 , -OCOOR 11 , -OCONR 12 R 13 , -OCHR 14 O.C.O.R. 15 Or -OCHR 14 OCOOR 15a where R 10 , R 11 And R 15 and R 15a is independently alkyl or alkyl substituted with amino, carboxy, or hydroxy; R 12 and R13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxy, or hydroxy, or R 12 and R 13 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl, and each R 14 is hydrogen, alkyl or haloalkyl; R 2 is hydrogen, deuterium, alkyl, halo, haloalkyl, alkenyl, or alkynyl; R 2a is hydrogen, halo, or deuterium; R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or R 3 and R 4 together with the carbon to which they are attached form an oxo, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered optionally substituted heterocyclylene; R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy; R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or R 5 and R 6 together with the carbon to which they are attached form an oxo, an alkyldienyl, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered optionally substituted heterocyclylene; with the proviso that R 5 and R 6 And R 3 and R 4 do not simultaneously form, together with the carbon to which they are attached, an oxo, a cycloalkylene, or an optionally substituted 4- to 6-membered heterocyclylene; R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl, or haloalkoxy; L is a bond, S, SO, SO2, O, CO or NR16 where R 16 is hydrogen or alkyl; R 8 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl, where aryl or heteroaryl, respectively by themselves or as part of an aralkyl or heteroaralkyl, or heterocyclyl by itself or as part of a heterocyclylalkyl, is R a , R b , R c , R g and R h where R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h is independently selected from hydrogen, deuterium, and halo; and R 9 R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, alkylsulfonyl, or heteroaryl, where heteroaryl is independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, and cyano. d , R e and R f optionally substituted with; or R 9 and R 2are attached to the same carbon atom, they can combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene; R 9a is hydrogen, halo, or deuterium) and pharma- ceutically acceptable salts thereof.
[0014] In a first embodiment of the first aspect, a compound of formula (I): [ka] (In the formula, X 1 is CH or N; R 1 are hydroxy, halo, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 , -OCOOR 11 , -OCONR 12 R 13 , -OCHR 14 O.C.O.R. 15 Or -OCHR 14 OCOOR 15a where R 10 , R 11 And R 15 and R 15a is independently alkyl or alkyl substituted with amino, carboxy, or hydroxy; R 12 and R 13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxy, or hydroxy, or R 12 and R 13 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl, and each R 14 is hydrogen, alkyl or haloalkyl; R 2 is hydrogen, deuterium, alkyl, halo, haloalkyl, alkenyl, or alkynyl; R 3 and R 4is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or R 3 and R 4 together with the carbon to which they are attached form an oxo, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered optionally substituted heterocyclylene; R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy; R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or R 5 and R 6 together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene or a 4- to 6-membered optionally substituted heterocyclylene; provided that R 5 and R 6 And R 3 and R 4 do not simultaneously form, together with the carbon to which they are attached, a cycloalkylene or an optionally substituted 4- to 6-membered heterocyclylene; R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl, or haloalkoxy; L is a bond, S, SO, SO2, O, CO or NR 16 where R 16 is hydrogen or alkyl; R 8R is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl, where aryl or heteroaryl, each by itself or as part of an aralkyl or heteroaralkyl, or heterocyclyl by itself or as part of a heterocyclylalkyl, is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. a , R b and R c is substituted with; and R 9 R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, alkylsulfonyl, or heteroaryl, where heteroaryl is independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, and cyano. d , R e and R f optionally substituted with; or R 9 and R 2 are attached to the same carbon atom, they can combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene. and pharma- ceutically acceptable salts thereof.
[0015] Provided is a crystalline form of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (Compound 5), designated as the crystalline Form A polymorph, having an X-ray powder diffraction pattern including peaks at angular positions 15.8 and 18.6, wherein the angular positions are determined by X-ray powder diffraction using an X-ray wavelength of 1.5418 Å (Cu Kα). ± In a first embodiment of the second aspect, the crystalline Form A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 15.8, 18.6 and 20.1, the angular positions being: ± In a second embodiment of the second aspect, the crystalline Form A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 12.9, 15.8, 18.6 and 20.1, the angular positions being: ± In a third embodiment of the second aspect, the crystalline Form A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 11.4, 12.9, 15.8, 18.6 and 20.1, the angular positions being: ± In a fourth embodiment of the second aspect, the crystalline Form A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 10.0, 11.4, 12.9, 15.8, 18.6 and 20.1, the angular positions being: ± In a fifth embodiment of the second aspect, the crystalline Form A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at the angular positions shown in Table A below, the angular positions being: ± In a sixth embodiment of the second aspect, the crystalline Form A polymorph exhibits an X-ray powder diffraction pattern comprising at least one peak (in some embodiments at least two peaks, at least three peaks, at least four peaks, or at least five peaks) at the angular positions shown in Table A below, the angular positions being: ± It can vary by 0.2°θ.
[0016] [Table 1]
[0017] [Table 2]
[0018] In a sixth embodiment of the second aspect, the crystalline form A polymorph exhibits an X-ray powder diffraction pattern substantially as shown in Figure 1. Substantially used for the sixth embodiment is ±0.2°2θ. In a seventh embodiment of the second aspect and the first to sixth embodiments thereof, the peaks shown therein have a tolerance of ±0.1°2θ.
[0019] In a third aspect, the disclosure relates to a method of treating a disease treatable by inhibition of HIF-2α in a patient, preferably a patient in need of such treatment, comprising administering to the patient, preferably a patient in need of such treatment, a therapeutically effective amount of (i) a compound of formula (IA) or (I) (or any of the embodiments thereof described herein) or a pharma- ceutically acceptable salt thereof; or (ii) the crystalline Form A polymorph of compound 5 as defined in the second aspect above, or any one of its embodiments thereof.
[0020] In one embodiment of the third aspect, the disease is a cancer such as renal carcinoma, glioblastoma (see PNAS 2017, 114, E6137-E6146), renal cell carcinoma, neuroblastoma, pheochromocytoma and paraganglioma (see European Journal of Cancer 2017, 86, 1-4), somatostatinoma, hemangioblastoma, gastrointestinal stromal tumor (GIST), pituitary tumor, leiomyoma, leiomyosarcoma, multiple cell carcinoma or retinal tumor. In another embodiment, non-cancerous diseases that may benefit from Hif-2α inhibition include VHL (von Hippel-Lindau) disease (see Oncotarget, 2015, 6, 23036-23037), PAH (pulmonary arterial hypertension) (see Mol. Cell. Biol. 2016, 36, 1584-1594), gastroesophageal reflux disease (see Current Opinion in Pharmacology 2017, 37:93-99), fatty liver (see Nature Medicine 2017, 23, 1298-1308), inflammatory diseases such as NASH, inflammatory bowel disease (see Nature Reviews gastroenterology & Hepatology 2017, 14, 596), autoimmune diseases such as graft versus host disease (see Blood, 2015, 126, 1865), or iron overload.
[0021] In a fourth aspect, the present disclosure relates to a pharmaceutical composition comprising: (i) a compound of formula (IA) or (I) (or any of the embodiments thereof described herein) or a pharma- ceutically acceptable salt thereof; or (ii) the crystalline form A polymorph of compound 5 as defined in the second aspect above, or any one of its embodiments; and a pharma- ceutically acceptable excipient. The present disclosure relates to a pharmaceutical composition prepared with the crystalline form A polymorph of compound 5 as defined in the second aspect above, or any one of its embodiments; and a pharma- ceutically acceptable excipient.
[0022] In a fifth aspect, the disclosure relates to (i) a compound of formula (IA) or (I) (or any of their embodiments described herein) or a pharma- ceutically acceptable salt thereof, or (ii) the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments, for use as a medicament. In one embodiment, the compound of formula (I) (and any of its embodiments described herein) or a pharma- ceutically acceptable salt thereof or the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments, is useful for the treatment of one or more diseases disclosed in the third aspect above.
[0023] A sixth aspect provided is the use of (i) a compound of formula (IA) or (I) or a pharma- ceutically acceptable salt thereof (and any embodiment thereof disclosed herein); or (ii) the crystalline Form A polymorph of compound 5 as de?ned in the second aspect above, or any one of its embodiments, in the manufacture of a medicament for treating a disease in a patient Wherein activity of HIF2a contributes to the pathology and / or symptoms of the disease. In one embodiment, the disease is one or more of the diseases disclosed in the third aspect above.
[0024] A seventh aspect is provided which is a method of inhibiting HIF2α, the method comprising contacting HIF2α with (i) a compound of formula (IA) or (I) (or any of their embodiments described herein) or a pharma- ceutically acceptable salt thereof; or (ii) the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments; or contacting HIF2α with a pharmaceutical composition comprising (i) a compound of formula (IA) or (I) (or any of their embodiments described herein) or a pharma- ceutically acceptable salt thereof; or (ii) the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments; and a pharma- ceutically acceptable excipient.
[0025] In any of the foregoing aspects relating to the treatment of cancer, further embodiments include the use of the EGFR inhibitors gefitinib, erlotinib, afatinib, icotinib, NeratinibIn another embodiment, the compound of formula (IA) or (I) or a pharma- ceutically acceptable salt thereof (or any of the embodiments thereof disclosed herein) or (ii) the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments is administered in combination with at least one additional anti-cancer agent such as rociletinib, cetuximab, panitumumab, zalutumumab, nimotuzumab or matuzumab. In another embodiment, the compound of formula (IA) or (I) (and any of the embodiments thereof described herein) or a pharma- ceutically acceptable salt thereof or the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments is administered in combination with a HER2 / neu inhibitor, including lapatinib, trastuzumab and pertuzumab. In another embodiment, the compound of formula (IA) or (I) (and any embodiment thereof described herein) or a pharma- ceutically acceptable salt thereof or the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments is administered in combination with a PI3k / mTOR inhibitor, including idelalisib, buparlisib, BYL719 and LY3023414. In another embodiment, the compound of formula (IA) or (I) (and any embodiment thereof described herein) or a pharma- ceutically acceptable salt thereof or the crystalline form A polymorph of compound 5 defined in the second aspect above or any one of its embodiments is administered in combination with a VEGF inhibitor, such as bevacizumab, and / or a multi-tyrosine kinase inhibitor, such as sorafenib, sunitinib, pazopanib and cabozantinib.In another embodiment, the compound of formula (IA) or (I) (and any embodiment thereof described herein) or a pharma- ceutically acceptable salt thereof or the crystalline Form A polymorph of Compound 5 defined in the second aspect above or any one of its embodiments is administered in combination with an immunotherapeutic agent such as a PD-1 and PD-L1 inhibitor, a CTLA4 inhibitor, an IDO inhibitor, a TDO inhibitor, an A2A agonist, an A2B agonist, a STING agonist, a RIG-1 agonist, a Tyro / Axl / Mer inhibitor, a glutaminase inhibitor, an arginase inhibitor, a CD73 inhibitor, a CD39 inhibitor, a TGF-β inhibitor, an IL-2, an interferon, a PI3K-γ inhibitor, a CSF-1R inhibitor, a GITR agonist, an OX40 agonist, a TIM-3 antagonist, a LAG-3 antagonist, a CAR-T therapy, and a therapeutic vaccine. When a combination therapy is used, the agents can be administered simultaneously or sequentially.
[0026] In an eighth embodiment, R 2 is hydrogen and R 9 is hydroxy, and X 1 , R 2 is hydrogen and R 1 , R 3 ~R 8 , L, R 2a and R 9a However, the first embodiment, i.e., formula (IA-1): [ka] A process for making a compound of formula (IA) is provided, which comprises the steps of: 2 and R 9 together with the carbon atom to which they are attached form an oxo, X 1 , R 1 , R 3 ~R 8 , L, R 2a and R 9a However, the above first embodiment, i.e., formula (IA-2): [ka] This involves treating a compound of formula (IA), which is as defined above, with a suitable reducing agent.
[0027] In a first embodiment of the eighth aspect, in each compound of formula (IA-1) and (IA-2), X 1 is CH and R 1 is hydroxy and R 3 , R 4 , R 5 and R 6 is fluoro and R 7 , R 2a and R 9a is hydrogen, L is O, and R 8 is 3-cyano-5-fluorophenyl.
[0028] In a ninth embodiment, R 2 is hydrogen and R 9 is fluoro, and X 1 , R 1 , R 3 ~R 8 , L, R 2a and R 9a However, the above first embodiment, i.e., formula (IA-3): [ka] A process for making a compound of formula (IA) is provided, which comprises the steps of: 2 is hydrogen and R 9 is hydroxy, and X 1 , R 1 , R 3 ~R 8 , L, R 2a and R 9a However, the first embodiment, i.e., formula (IA-1): [ka] This involves treating a compound of formula (I), which is as defined above, with a suitable fluorinating agent.
[0029] In a first embodiment of the ninth aspect, in each compound of formula (IA-3) and (IA-1), X 1 is CH and R 1 is hydroxy and R 3 , R 4 , R 5 and R 6 is fluoro and R 7 , R 2a and R 9a is hydrogen, L is O, and R 8 is 3-cyano-5-fluorophenyl.
[0030] In a ninth aspect, there is provided a process for making the crystalline form A polymorph of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile from a composition comprising the steps of: a) contacting 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile with one or more solvents selected from the group consisting of n-pentanol, heptane, methanol (MeOH), isopropanol (IPA), methyl tert-butyl ether (MTBE), ethyl acetate (EtOAc), isopropyl acetate (IPAc), toluene, acetone, acetonitrile (ACN), 1,4-dioxane and ethanol (EtOH); preferably n-pentanol and heptane; at a temperature selected from about room temperature to about 60° C., preferably about 50° C.; b) cooling the mixture to about room temperature; and c) filtering the crystalline form A polymorph of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile from the mixture; A process is provided that includes: [Brief description of the drawings]
[0031] [Figure 1] FIG. 2 shows a representative XRPD diffractogram of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile, crystalline form A polymorph of compound 5, crystallized from pentanol and hexane according to the method described in Example 25. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] Definition: Unless otherwise stated, the following terms used in the specification and claims are defined for purposes of this application and have the following meanings:
[0033] "Alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl, pentyl, etc. It will be recognized by those skilled in the art that the term "alkyl" can include "alkylene" groups.
[0034] "Alkylene", unless otherwise specified, means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, propylene, 1-methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
[0035] "Alkenyl" means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing a double bond, e.g., propenyl, butenyl, and the like.
[0036] An "alkyldienyl" is an alkenyl as defined above attached through a terminal divalent carbon. For example, the compound: [ka] In the above formula, the alkyldienyl group is enclosed in a box indicated by an arrow.
[0037] "Haloalkyldienyl" refers to an alkyldienyl substituted with one or two halo, each group being defined herein.
[0038] "Alkynyl" means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms containing a triple bond, e.g., propynyl, butynyl, and the like.
[0039] "Alkylthio" means a -SR radical where R is alkyl as defined above, e.g., methylthio, ethylthio, and the like.
[0040] "Alkylsulfonyl" means a -SO2R radical where R is alkyl as defined above, e.g., methylsulfonyl, ethylsulfonyl, and the like.
[0041] "Alkyl sulfoxide" means a -SOR radical where R is alkyl as defined above, e.g., methyl sulfoxide, ethyl sulfoxide, and the like.
[0042] "Amino" means --NH2.
[0043] "Alkylamino" means an --NHR radical where R is alkyl as defined above, e.g., methylamino, ethylamino, propylamino, or 2-propylamino, and the like.
[0044] "Aminoalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted by -NR'R'', where R' and R'' are each independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or alkylcarbonyl, as defined herein, e.g., aminomethyl, aminoethyl, methylaminomethyl, and the like.
[0045] "Alkoxy" means an --OR radical where R is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, and the like.
[0046] "Alkoxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons, which is substituted with at least one alkoxy group, such as one or two alkoxy groups, as defined above, e.g., 2-methoxyethyl, 1-, 2-, or 3-methoxypropyl, 2-ethoxyethyl, and the like.
[0047] "Alkoxycarbonyl" means a -C(O)OR radical where R is alkyl as defined above, e.g., methoxycarbonyl, ethoxycarbonyl, and the like.
[0048] "Alkylcarbonyl" means a -C(O)R radical where R is alkyl as defined herein, e.g., methylcarbonyl, ethylcarbonyl, and the like.
[0049] "Aryl" means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms, e.g., phenyl or naphthyl.
[0050] "Aralkyl" means an -(alkylene)-R radical where R is aryl as defined above, e.g., benzyl, phenethyl, and the like.
[0051] "Bicyclic cycloalkyl" means a fused bicyclic saturated monovalent hydrocarbon radical of 6 to 10 carbon atoms, optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano. Examples include, but are not limited to, decalin, octahydro-1H-indene, and the like.
[0052] "Cycloalkyl" means a monocyclic saturated monovalent hydrocarbon radical of 3 to 10 carbon atoms optionally substituted with one or two substituents independently selected from alkyl, alkyldienyl, halo, alkoxy, hydroxy, cyano, haloalkyldienyl, and cyanoalkyl. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyanocycloprop-1-yl, 1-cyanomethylcycloprop-1-yl, 3-fluorocyclohexyl, and the like. Cycloalkyl can include cycloalkylene as defined herein.
[0053] "Cycloalkylalkyl" means an -(alkylene)-R radical where R is cycloalkyl as defined above, e.g., cyclopropylmethyl, cyclohexylmethyl, and the like.
[0054] "Cycloalkylene" means a divalent cycloalkyl as defined above, unless otherwise specified.
[0055] "Cycloalkenyl" means a monocyclic monovalent hydrocarbon radical of 3 to 10 carbon atoms containing one or two double bonds, optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, cyano, and cyanoalkyl. Examples include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl, and the like.
[0056] "Oxocycloalkenyl" means a monocyclic monovalent hydrocarbon radical of 3 to 10 carbon atoms containing one or two double bonds and an oxo group, optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, cyano, and cyanoalkyl. Examples include, but are not limited to, 3-oxocyclohex-1-enyl, and the like.
[0057] "Cyanoalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with cyano, e.g., cyanomethyl, cyanoethyl, and the like.
[0058] "Carboxy" means --COOH.
[0059] "Dialkylamino" means an --NRR' radical where R and R' are alkyl as defined above, e.g., dimethylamino, methylethylamino, and the like.
[0060] "Disubstituted amino" means an --NRR' radical where R and R' are independently alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or alkylcarbonyl, each as defined herein, e.g., dimethylamino, ethylmethylamino, bis-hydroxyethylamino, bis-methoxyethylamino, diethylaminoethylamino, and the like.
[0061] "Halo" means fluoro, chloro, bromo or iodo, preferably fluoro or chloro.
[0062] "Haloalkyl" means an alkyl radical as defined above that is substituted with one or more halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., 1 to 5 halogen atoms, e.g., -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, etc. When an alkyl is substituted with only fluoro, it may be referred to in this application as a fluoroalkyl.
[0063] "Haloalkoxy" means an -OR radical where R is haloalkyl as defined above, e.g., -OCF, -OCHF, etc. When R is haloalkyl and the alkyl is substituted with only fluoro, it is referred to in this application as fluoroalkoxy.
[0064] "Hydroxyalkyl" means a linear monovalent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present, they are not both on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl, and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl, and 1-(hydroxymethyl)-2-hydroxyethyl.
[0065] "Heterocyclyl" refers to a heterocyclic ring in which one or two ring atoms are N, O, or S(O). nwhere n is an integer from 0 to 2, and the remaining ring atoms are C, unless otherwise specified. In addition, one or two ring carbon atoms of the heterocyclyl ring can be optionally substituted with a -CO- group. More specifically, the term heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino, tetrahydro-pyranyl, thiomorpholino, and the like. When the heterocyclyl ring is unsaturated, it can contain one or two ring double bonds, as long as the ring is not aromatic. When a heterocyclyl group contains at least one nitrogen atom, it is also referred to herein as heterocycloamino, and is a subset of the heterocyclyl group.
[0066] "Heterocyclylalkyl" or "heterocycloalkyl" means an -(alkylene)-R radical where R is a heterocyclyl ring as defined above, e.g., tetrahydrofuranylmethyl, piperazinylmethyl, morpholinylethyl, and the like.
[0067] "Heterocyclylene" means a divalent heterocyclyl as defined above, unless otherwise specified. If the heterocyclylene contains 4, 5 or 6 ring atoms, it may be referred to herein as a 4- to 6-membered heterocyclylene.
[0068] "Heteroaryl" means, unless otherwise specified, a monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms, where one or more (in one embodiment, one, two or three) ring atoms are heteroatoms selected from N, O or S, and the remaining ring atoms are carbon. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like. As defined herein, the terms "heteroaryl" and "aryl" are mutually exclusive. When a heteroaryl ring contains 5 or 6 ring atoms, it is also referred to herein as a 5- or 6-membered heteroaryl.
[0069] "Heteroarylene" means a divalent heteroaryl radical as defined above.
[0070] "Heteroaralkyl" means a -(alkylene)-R radical where R is heteroaryl as defined above, e.g., pyridinylmethyl, etc. When the heteroaryl ring of the heteroaralkyl contains 5 or 6 ring atoms, it is also referred to herein as a 5- or 6-membered heteroaralkyl.
[0071] "R 2 and R 9 is R 1 The phrase "bonded to a ring carbon atom that is meta to a ring carbon bonded to R" is intended to mean 2 and R 9 are arranged as shown below. [ka]
[0072] The term "oxo" as used herein, alone or in combination, refers to =(O).
[0073] Any definition herein may be used in combination with other definitions to describe composite structural groups, as necessary. By convention, the last element of such definitions is the element that is attached to the parent moiety. For example, the composite group alkoxyalkyl means that the alkoxy group is attached to the parent molecule via an alkyl group.
[0074] The present disclosure also includes protected derivatives of compounds of formula (IA) or (I). For example, when compounds of formula (IA) or (I) contain groups such as hydroxy, carboxy, thiol, or any group containing a nitrogen atom, these groups can be protected with a suitable protecting group. A comprehensive list of suitable protecting groups can be found in TW Greene, Protective Groups in Organic Synthesis, 5 th Ed., John Wiley & Sons, Inc. (2014), the disclosure of which is incorporated herein by reference in its entirety. Protected derivatives of the compounds of the present disclosure can be prepared by methods known in the art.
[0075] The present disclosure also includes polymorphs of the compounds of formula (IA) or (I) or their pharma- ceutically acceptable salts. Polymorphs are different crystalline forms of a compound that differ in the arrangement of the molecules of that compound in the crystal lattice. Thus, a single compound can give rise to various polymorphs. Polymorphs of a compound usually have different melting points, solubilities, densities and optical properties. Polymorphs of a compound can be distinguished by several techniques, such as X-ray diffraction measurement, IR or Raman spectroscopy.
[0076] "XRPD" means X-ray powder diffraction, an analytical technique that measures the diffraction of X-rays in the presence of solid components. Substances that are crystalline, that is, have a regular repeating arrangement of atoms, produce unique powder patterns.
[0077] As used herein, "poor solvent" refers to a solvent in which the compound of formula (IA) or (I) is poorly soluble.
[0078] The term "prodrug" refers to a compound that is more active in vivo. Certain compounds of formula (IA) or (I) may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of compounds of formula (IA) or (I) are structurally modified forms of the compounds that readily undergo chemical changes under physiological conditions to provide the active compound. Prodrugs are often useful because in some situations they may be easier to administer than the compound or parent drug. They may be bioavailable, for example, by oral administration, whereas the parent drug is not bioavailable. A variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. Examples of prodrugs include, but are not limited to, compounds that are administered as esters, but are subsequently metabolically hydrolyzed to the carboxylic acid, the active entity ("prodrug"). Further examples include peptidyl derivatives of the compounds of formula (IA) or (I).
[0079] A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: Acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, acid, acid addition salts formed with organic acids such as benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or Salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., either an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordination with organic bases such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc. It is understood that pharma- ceutically acceptable salts are non-toxic. Additional information regarding suitable pharma- ceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference in its entirety.
[0080] Compounds of formula (IA) or (I) may have asymmetric centers. Compounds of formula (IA) or (I) containing asymmetrically substituted atoms may be isolated in optically active or racemic form. Individual stereoisomers of the compounds may be prepared synthetically from commercially available starting materials containing chiral centers, or by separation, such as preparation of a mixture of enantiomeric products followed by conversion to a mixture of diastereomers, followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on a chiral chromatographic column, or other suitable methods known in the art. Unless a particular stereochemistry or isomeric form is specifically indicated, all chiral, diastereomeric, all mixtures of chiral or diastereomeric forms and racemic forms are within the scope of this disclosure. It will also be understood by those skilled in the art that when a compound is indicated as an (R) stereoisomer, it may contain the corresponding (S) stereoisomer as an impurity, and vice versa.
[0081] Certain compounds of formula (IA) or (I) may exist as tautomers and / or geometric isomers. All possible tautomers, both individually and in their mixtures, as well as cis and trans isomers, are within the scope of this disclosure. Furthermore, as used herein, the term alkyl includes all possible isomeric forms of said alkyl groups, although only a few examples are shown. Furthermore, when cyclic groups such as aryl, heteroaryl, heterocyclyl are substituted, they include all positional isomers, although only a few examples are shown. Furthermore, all hydrates of compounds of formula (IA) and (I) are within the scope of this disclosure.
[0082] Compounds of formula (IA) or (I) may also contain unusual amounts of isotopes at one or more atoms that constitute such compounds. An unusual amount of isotope may be defined as ranging from the amount found in nature to 100% of the amount of the atom in question, differing only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of formula (IA) or (I) (and any embodiment thereof disclosed herein, including specific compounds) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine (respectively). 2H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I, 125 Isotopically labeled compounds (e.g., 3 H and 14 C) can be useful in compound or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes can be useful for their ease of preparation and detectability. Additionally, deuterium (i.e. 2 Substitution with heavier isotopes, such as H, may confer certain therapeutic advantages (e.g., increased in vivo half-life or reduced required dosage) resulting from greater metabolic stability. In some embodiments, in the compounds disclosed herein, including in Table 1 below, one or more hydrogen atoms are 2 H or 3 H or one or more carbon atoms are replaced by 13 C or 14 Replaced by C-rich carbon. 15 O. 13 N, 11 C and 15 Positron emitting isotopes such as F are useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the schemes or examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
[0083] Certain structures provided herein are drawn with one or more variable substituents. Unless otherwise specified or apparent from the context, a substituent may be present on any atom of the ring to which it is attached, where chemically feasible and valence rules permit. For example, the structure: [ka] In R 7 The substituent is X 1 Any hydrogen on the benzo portion of the tricyclic ring can be replaced, including the hydrogen of CH when is CH.
[0084] "Optionally substituted aryl" means aryl optionally substituted with one, two or three substituents independently selected from alkyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfonyl, amino, alkylamino, dialkylamino, halo, haloalkyl, haloalkoxy, and cyano.
[0085] "Optionally substituted heteroaryl" means heteroaryl as defined above optionally substituted with one, two or three substituents independently selected from alkyl, alkylthio, alkylsulfonyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino and cyano.
[0086] "Optionally substituted heterocyclyl" means, unless otherwise stated, a heterocyclyl as defined above optionally substituted with one, two or three substituents independently selected from alkyl, alkylthio, alkylsulfonyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aminoalkyl, halo, haloalkyl, haloalkoxy and cyano.
[0087] An "optionally substituted heterocyclylene" is a divalent optionally substituted heterocyclyl as defined above.
[0088] "Pharmaceutically acceptable carrier or excipient" means a carrier or excipient that is generally safe, non-toxic, and not biologically or otherwise undesirable and is useful in preparing pharmaceutical compositions, and includes carriers or excipients acceptable for veterinary and human medicine. As used in the specification and claims, "pharmaceutically acceptable carrier / excipient" includes both one and more than one such excipient.
[0089] "Spirocycloalkyl" means a saturated bicyclic ring having 6 to 10 ring carbon atoms, in which the rings are connected through only one atom, the connecting atom, also called a spiro atom, most often a quaternary carbon ("spiro carbon"). The spirocycloalkyl ring is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano. Representative examples include, but are not limited to, spiro[3.3]heptane, spiro[3.4]octane, spiro[3.5]nonane, spiro[4.4]nonane (1:2:1:1), and the like.
[0090] "Spiroheterocyclyl" refers to a heterocyclic ring in which one, two or three ring atoms are N, O or S(O). nwherein n is an integer from 0 to 2, the remaining ring atoms are C, and the rings are connected through only one atom, the connecting atom also referred to as a spiro atom, most often a quaternary carbon ("spiro carbon"). The spiroheterocyclyl ring is optionally substituted with one, two, or three substituents independently selected from alkyl, alkylthio, alkylsulfonyl, hydroxyl, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aminoalkyl, halo, haloalkyl, haloalkoxy, and cyano. Representative examples include, but are not limited to, 2,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2-azaspiro[3.4]octane, 2-azaspiro[3.5]nonane, 2,7-diazaspiro[4.4]nonane, and the like.
[0091] The term "about" as used herein is intended to specify the numerical value it modifies and indicates such value as variable within a margin of error. When no particular margin of error is stated, such as a standard deviation to the average value stated in a chart or table of data, the term "about" should be understood to mean a range that includes the stated value and range, and that would encompass ±10%, preferably ±5%.
[0092] R in formula (I) 9 In the definition of "R independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, and cyano," d , R e and R f The phrase "heteroaryl optionally substituted with" (and similar phrases used to define other groups in formula (I)) refers to unsubstituted heteroaryl as well as R d , R e and R f It is intended to encompass heteroaryl substituted with any one of:
[0093] The term "disease" as used herein is generally intended to be synonymous and is used interchangeably with the terms "disorder," "syndrome," and "condition" (as in medical condition), in that all reflect an abnormal condition of the human or animal body or one of its parts that impairs normal functioning, typically indicated by distinguishing signs and symptoms, and causing a decrease in the duration or quality of life of the human or animal.
[0094] The term "combination therapy" refers to the administration of two or more therapeutic agents to treat a disease or disorder described in this disclosure. Such administration includes co-administration of these therapeutic agents in a substantially simultaneous manner, such as a single capsule having a fixed ratio of active ingredients or separate multiple capsules for each active ingredient. Furthermore, such administration also includes the use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen provides the beneficial effect of the drug combination in treating the condition or disorder described herein.
[0095] The term "patient" is generally synonymous with the term "subject" and includes all mammals, including humans. Examples of patients include humans, domestic animals such as cows, goats, sheep, pigs and rabbits, and companion animals such as dogs, cats, rabbits and horses. Preferably, the patient is a human.
[0096] "Treating" a disease or "treatment" of a disease includes: (1) To prevent the disease, i.e., to prevent the development of clinical symptoms of the disease in a mammal that is exposed to or susceptible to the disease, but which may still not experience or exhibit symptoms of the disease; (2) inhibiting the disease, i.e., preventing or reducing the onset of the disease or its clinical symptoms; or (3) alleviating the disease, i.e., causing regression of the disease or its clinical symptoms; Includes:
[0097] "Therapeutically effective amount" means the amount of a compound of the present disclosure, or a pharma- ceutically acceptable salt thereof, that, when administered to a patient for treating a disease, is sufficient to affect such treatment of the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal being treated.
[0098] The terms "inhibit" and "reduce" or any variation of these terms relating to HIF-2α include a measurable decrease or complete inhibition to achieve a desired result, such as about, up to about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein, a decrease in HIF-2α activity compared to normal.
[0099] Embodiments: In further embodiments 1-30 below, the present disclosure includes the following:
[0100] 1A. In embodiment 1A, the compound of formula (IA): [ka] The compound of is as described in the first aspect of the summary above. In a subembodiment of embodiment 1A, R 2a and R 9a is independently hydrogen or deuterium.
[0101] 1. In embodiment 1, the compound of formula (I): [ka] The compound of is as described in the first embodiment of the aspect in the summary above.
[0102] In embodiment 1A or 1 or a first subembodiment of a subembodiment within embodiment 1A, the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 1 is hydroxy.
[0103] In an embodiment of embodiment 1A or 1 or a second subembodiment of the subembodiment within embodiment 1A, the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 1 is amino or halo, preferably R 1 is an amino.
[0104] In an embodiment of embodiment 1A or 1 or a third subembodiment of the subembodiment within embodiment 1A, the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 1 Ga-OCOR 10 , -OCOOR 11 , -OCONR 12 R 13 , -OCHR 14 O.C.O.R. 15 Or -OCHR 14 OCOOR 15a where R 10 , R 11 , R 15 and R 15a is as defined in the overview.
[0105] In an embodiment of embodiment 1A or 1 or a fourth subembodiment of the subembodiment within embodiment 1A, the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 1 is -OP(O)(OH)2 or -OCH2OP(O)(OH)2.
[0106] In a fifth subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third and fourth subembodiments above), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 6 is halo, preferably R 6 is fluoro.
[0107] In a sixth subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third and fourth subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 6 is alkyl, preferably R 6 is methyl.
[0108] In a seventh subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third and fourth subembodiments), the compound of formula (IA), (I) or a pharmaceutical salt thereof is 6 is hydrogen or deuterium.
[0109] In an eighth subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third and fourth subembodiments), the compound of formula (1A) or (I) or a pharmaceutical salt thereof is 6 is cycloalkyl, preferably R 6 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0110] In a ninth subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third, fourth, fifth, sixth, seventh and eighth subembodiments above), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 5 is halo or haloalkyl, preferably R 5 is difluoromethyl or trifluoromethyl.
[0111] In a tenth subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third, fourth, fifth, sixth, seventh and eighth subembodiments above), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 5is alkyl, preferably R 5 is methyl or ethyl.
[0112] In an eleventh subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third, fourth, fifth, sixth, seventh and eighth subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 5 is hydrogen or alkoxy.
[0113] In a twelfth subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third and fourth subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 5 and R 6 together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene, preferably R 5 and R 6 together with the carbon to which they are attached form a cyclopropylene, cyclobutylene, or cyclopentylene, each optionally substituted with one or two fluoro.
[0114] In a thirteenth subembodiment of embodiment 1A or 1 or subembodiments within embodiment 1A and subembodiments therein (i.e., the first, second, third and fourth subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 5 and R 6 together with the carbon to which they are attached form a 4-6 membered optionally substituted heterocyclylene, preferably R 5 and R 6 along with the carbons to which they are attached. [ka] This forms the
[0115] In a fourteenth subembodiment of embodiment 1A or 1 or any subembodiment within embodiment 1A (i.e., the first to eleventh subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 3 and R 4 are independently halo.
[0116] In a fifteenth subembodiment of embodiment 1A or 1 or any subembodiment within embodiment 1A (i.e., the first to eleventh subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 3 is the halo, and R 4 is hydrogen.
[0117] In a sixteenth subembodiment of embodiment 1A or 1 or any subembodiment within embodiment 1A and subembodiments therein (i.e., the first to fifteenth subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 1 CH or CR 7 It is what it is.
[0118] In a 17th subembodiment of embodiment 1A or 1 or any subembodiment within embodiment 1A and subembodiments therein (i.e., the 1st to 15th subembodiments), the compound of formula (IA) or (I) or a pharmaceutical salt thereof is 1 where N.
[0119] 2A. In embodiment 2A, the compound of embodiment 1A, or a pharma- ceutically acceptable salt thereof, has the formula (IIa1) or (IIb1): [ka] It has the structure:
[0120] In a first subembodiment of Embodiment 2A, the compound or subembodiment within Embodiment 1A or a pharma- ceutically acceptable salt thereof has the structure of Formula (IIa1). In a second subembodiment of Embodiment 2A, the compound or a pharma- ceutically acceptable salt thereof has the structure of Formula (IIb1).
[0121] 2Aa. In embodiment 2Aa, the compound of embodiment 1A or a subembodiment within embodiment 1A, or a pharma- ceutically acceptable salt thereof, has the formula (IIa1') or (IIb1') [ka] It has the structure:
[0122] In a first subembodiment of embodiment 2Aa, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIa1'). In a second subembodiment of embodiment 2Aa, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIb1').
[0123] 2. In embodiment 2, the compound of embodiment 1 or a pharma- ceutically acceptable salt thereof has the formula (IIa) or (IIb): [ka] It has the structure:
[0124] In a first subembodiment of embodiment 2, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IIa).In a second subembodiment of embodiment 2, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IIb).
[0125] 2a. In embodiment 2a, the compound of embodiment 1, or a pharma- ceutically acceptable salt thereof, has the formula (IIa') or (IIb'): [ka] It has the structure:
[0126] In a first subembodiment of embodiment 2a, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIa'). In a second subembodiment of embodiment 2a, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIb').
[0127] 3A. In embodiment 3A, the compound of embodiment 1A or a subembodiment within embodiment 1A, or a pharma- ceutically acceptable salt thereof, has the formula (IIIa1) or (IIIb1): [ka] It has the structure:
[0128] In a first subembodiment of embodiment 3A, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IIIa1): In a second subembodiment of embodiment 3A, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IIIb1):
[0129] 3Aa. In embodiment 3Aa, the compound of embodiment 1A or a pharma- ceutically acceptable salt thereof has the formula (IIIa1') or (IIIb1'): [ka] It has the structure:
[0130] In a first subembodiment of embodiment 3Aa, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIIa1'). In a second subembodiment of embodiment 3Aa, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIIb1').
[0131] 3. In embodiment 3, the compound of embodiment 1, or a pharma- ceutically acceptable salt thereof, has the formula (IIIa) or (IIIb): [ka] It has the structure:
[0132] In a first subembodiment of embodiment 3, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IIIa): In a second subembodiment of embodiment 3, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IIIb):
[0133] 3a. In embodiment 3a, the compound of embodiment 1, or a pharma- ceutically acceptable salt thereof, has the formula (IIIa') or (IIIb'): [ka] It has the structure:
[0134] In a first subembodiment of embodiment 3a, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIIa'). In a second subembodiment of embodiment 3a, the compound or a pharma- ceutically acceptable salt thereof has the structure of formula (IIIb').
[0135] 4. In embodiment 4, the compound of embodiment 1 or a pharma- ceutically acceptable salt thereof has the formula (IVa) or (IVb): [ka] (In the formula, R 5 and R 6 together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene, preferably cyclopropylene, cyclobutylene or cyclopentylene, optionally substituted with one or two fluoro. In a first subembodiment of embodiment 4, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IVa). In a second subembodiment of embodiment 4, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (IVb).
[0136] 5. In embodiment 5, the compound of embodiment 1, or a pharma- ceutically acceptable salt thereof, has the formula (Va) or (Vb): [ka] (In the formula, R 5 and R 6 together with the carbon to which they are attached form a 4-6 membered optionally substituted heterocyclylene, preferably R 5 and R 6 along with the carbon to which they are attached. [ka] (form It has the structure:
[0137] In a first subembodiment of embodiment 5, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (Va): In a second subembodiment of embodiment 5, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (Vb):
[0138] 6. In embodiment 6, the compound of embodiment 1 or a pharma- ceutically acceptable salt thereof has the formula (VIa) or (VIb): [ka] (In the formula, R 5 and R 6 together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene, preferably cyclopropylene, cyclobutylene or cyclopentylene, optionally substituted with one or two fluoro. In a first subembodiment of embodiment 6, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (VIa). In a second subembodiment of embodiment 6, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (VIb).
[0139] 7A. In embodiment 7A, the compound of embodiment 1A, or a pharma- ceutically acceptable salt thereof, has the formula (VIIa1) or (VIIb1): [ka] It has the structure:
[0140] In a first subembodiment of embodiment 7A, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (VIIa1).In a second subembodiment of embodiment 7A, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (VIIb1).
[0141] 7. In embodiment 7, the compound of embodiment 1 or a pharma- ceutically acceptable salt thereof has the formula (VIIa) or (VIIb): [ka] It has the structure:
[0142] In a first subembodiment of embodiment 7, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (VIIa): In a second subembodiment of embodiment 7, the compound, or a pharma- ceutically acceptable salt thereof, has the structure of formula (VIIb):
[0143] 8. In embodiment 8, the compound of any one of embodiments 1A to 7 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and the subembodiments of embodiment 2A to 7) or a pharma- ceutically acceptable salt thereof, may comprise R 3 and R 4 In a first subembodiment, one of R is halo, preferably fluoro. 3 is fluoro and R 4 is hydrogen.
[0144] 9. In embodiment 9, the compound of any one of embodiments 1A to 7 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and subembodiments of embodiment 2A to 7) or a pharma- ceutically acceptable salt thereof, may comprise R 3 and R 4 is halo, preferably R 3 and R 4 is fluoro.
[0145] 10. In embodiment 10, the compound of any one of embodiments 1A-9 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiments 1A and / or 1, and subembodiments of embodiments 2A-9), or a pharma- ceutically acceptable salt thereof, wherein L is O, S, SO, SO2, or NH. In a first subembodiment of embodiment 10, L is O. In a second subembodiment of embodiment 10, L is S. In a third subembodiment of embodiment 10, L is NH. In a fourth subembodiment of embodiment 10, L is SO or SO2.
[0146] 11. In embodiment 11, the compound of any one of embodiments 1A to 10 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and subembodiments of embodiments 2A to 10) or a pharma- ceutically acceptable salt thereof, may comprise R 8R is cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl, where aryl or heteroaryl, each by itself or as part of an aralkyl or heteroaralkyl, or heterocyclyl by itself or as part of a heterocyclylalkyl, is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. a , R b and R c has been replaced with.
[0147] 12A. In embodiment 12A, the compound or pharma- ceutically acceptable salt thereof of any one of embodiments 1A, 2A, 2Aa, 3A, 3Aa, 7A, and 8-10 and subembodiments therein, is 8 But R a , R b , R c , R g and R h phenyl substituted with, where R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h is independently selected from hydrogen, deuterium, and halo. In a first subembodiment of embodiment 12A, R a , R b and R cis independently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, and cyano. In a second subembodiment of embodiment 12A, R a , R b and R c is independently selected from hydrogen, deuterium, methyl, methoxy, hydroxy, chloro, fluoro, cyano, difluoromethyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy, and R g and R h is independently hydrogen or deuterium. In a third subembodiment of embodiment 12A, R 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl Phenyl , 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, 3-cyano-5-difluoromethylphenyl, or 3-cyano-5-fluoro-2,4,6-trideuteriophenyl. In a fourth subembodiment of embodiment 12A, R 10 is 3-cyano-5-fluorophenyl or 3-cyano-5-fluoro-2,4,6-trideuteriophenyl.
[0148] 12. In embodiment 12, the compound of any one of embodiments 2, 2a, 3, 3a-6, and 7-10 and subembodiments therein (e.g., subembodiments 1-17 of embodiment 1 and subembodiments 2, 2a, 3, 3a-6, and 7-10 of embodiment 1), or a pharma- ceutically acceptable salt thereof, may comprise R 8R is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl; a , R b and R c In a first subembodiment of embodiment 12, R a , R b and R c is independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, and cyano. In a second subembodiment of embodiment 12, R a , R b and R c is independently selected from hydrogen, methyl, methoxy, hydroxy, chloro, fluoro, cyano, difluoromethyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy. 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl Phenyl In a fourth subembodiment of embodiment 12, R is selected from the group consisting of 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, and 3-cyano-5-difluoromethylphenyl. 10 is 3-cyano-5-fluorophenyl.
[0149] 13. In embodiment 13, the compound of any one of embodiments 1A to 10 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and subembodiments of embodiments 2A to 10) or a pharma- ceutically acceptable salt thereof may comprise R 8 In a first subembodiment of embodiment 13, R is cycloalkyl or cycloalkylalkyl, each optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, cyano, alkyldienyl, haloalkyldienyl, and hydroxy. 8 is cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, or cyclohexylmethyl, each of which is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, cyano, and hydroxy. In a second subembodiment of embodiment 13, R 6 is cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl or cyclohexylmethyl, each of which is substituted with one or two substituents independently selected from hydrogen, methyl, methoxy, cyano and fluoro, preferably R 8 In a third subembodiment of embodiment 13, R is cyclopropylmethyl, 1-cyanocyclopropylmethyl, cyclobutylmethyl, 2-fluorocyclopropylmethyl, or 1-cyanocyclobutylmethyl. 8 In a fourth subembodiment of embodiment 13, R is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, cyano, and hydroxy. 8 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, each optionally substituted with one or two substituents independently selected from methyl, cyano, methoxy and fluoro, preferably R 8is cyclobutyl, 3-fluorocyclobutyl, 3,3-difluorocyclobutyl, 3-cyanocyclobutyl, 3-fluorocyclohexyl or 3-cyano-3-methylcyclobutyl.
[0150] 14. In embodiment 14, the compound of any one of embodiments 1A to 10 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and subembodiments of embodiments 2A to 10) or a pharma- ceutically acceptable salt thereof, may comprise R 8 R is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl; a , R b and R c In a first subembodiment of embodiment 14, R 8 are R a , R b and R c 5- or 6-membered heteroaryl substituted with, for example, pyridyl, pyridazinyl, pyrimidinyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl or pyrazinyl, where R a and R b is independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, and cyano, and R c is selected from hydrogen, alkyl, halo, haloalkyl, and haloalkoxy. 8 are R a , R b and R cpyridin-3-yl, pyridin-2-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl, pyrimidin-2-yl, thien-2-yl, furan-2-yl, thiazol-5-yl, oxazol-5-yl, imidazol-5-yl, furan-3-yl, thien-3-yl, thiazol-4-yl, pyridin-4-yl, oxazol-2-yl, imidazol-2-yl, pyridin-2-yl, pyrazin-2-yl or thiazol-2-yl substituted with R a and R b is independently selected from hydrogen, methyl, methoxy, hydroxy, chloro, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy, and R c is selected from hydrogen, methyl, cyano, chloro, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy. 8 is 5-cyanopyridin-3-yl, 5-chloropyridin-3-yl or 5-fluoropyridin-3-yl.
[0151] 15. In embodiment 15, the compound of any one of embodiments 1A to 10 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and subembodiments of embodiments 2A to 10) or a pharma- ceutically acceptable salt thereof, may comprise R 8 But R a , R b and R c and bicyclic heteroaryl substituted with R a and R b is independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, and cyano, and R c is selected from hydrogen, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl.
[0152] 16. In embodiment 16, the compound of any one of embodiments 1A to 10 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and subembodiments of embodiments 2A to 10) or a pharma- ceutically acceptable salt thereof may comprise R 8 is heterocyclyl, where heterocyclyl is R a , R b and R c where R a and R b is independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, and cyano, and R c In a first subembodiment of embodiment 18, R is hydrogen, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, or aminoalkyl. 8 are each independently R a and R b substituted tetrahydrofuranyl, tetrahydrofuranyl Ropi aryl or oxetanyl, where R a and R b is independently selected from hydrogen, methyl and fluoro.
[0153] 17. In embodiment 17, the compound of any one of embodiments 1A to 10 and subembodiments therein (e.g., or subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and the subembodiments of embodiments 2A to 10) or a pharma- ceutically acceptable salt thereof, may comprise R 8 is spiroheterocyclyl. In one embodiment, the spiroheterocyclyl ring contains at least one nitrogen atom. In a second embodiment, the spiroheterocyclyl ring contains at least one oxygen atom.
[0154] 18. In embodiment 18, the compound of any one of embodiments 1A to 17 and subembodiments therein (e.g., subembodiments within embodiment 1A, subembodiments 1 to 17 of embodiments 1A and / or 1, and subembodiments of embodiments 2A to 17) or a pharma- ceutically acceptable salt thereof may comprise R 7 is hydrogen, methyl, ethyl, methoxy, fluoro, trifluoromethyl or trifluoromethoxy. 7 is hydrogen.
[0155] 19. In embodiment 19, the compound of any one of embodiments 1A to 18 and subembodiments therein (e.g., subembodiments within embodiment 1A, subembodiments 1 to 17 of embodiments 1A and / or 1, and subembodiments of embodiments 2A to 18) or a pharma- ceutically acceptable salt thereof may comprise R 2 is hydrogen, fluoro, methyl or ethyl. In a first subembodiment, R 2 is hydrogen. In a first subembodiment, R 2 is methyl. In a third subembodiment, R 2 is fluoro.
[0156] 20. In embodiment 20, the compound of any one of embodiments 1A to 19 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and the subembodiments of embodiments 2A to 19) or a pharma- ceutically acceptable salt thereof, may comprise R 9 is hydrogen, alkyl, halo, hydroxy, or alkoxy. In a first subembodiment of embodiment 20, R 9 is hydrogen, methyl, methoxy or fluoro.
[0157] 21. In embodiment 21, the compound of any one of embodiments 1A to 20 and subembodiments therein (e.g., subembodiments within embodiment 1A, the 1st to 17th subembodiments of embodiment 1A and / or 1, and subembodiments of embodiments 2A to 20) or a pharma- ceutically acceptable salt thereof, may comprise R 2 and R9 are attached to the same carbon atom. In a first subembodiment of embodiment 21, R 2 and R 9 is R 1 is bonded to a ring carbon atom that is meta to the ring carbon bonded to
[0158] 22A. In embodiment 22A, the compound or pharma- ceutically acceptable salt thereof of any one of embodiments 1A, 2A, 2Aa, 3A, 3Aa, 7A, 8-10, 12A, and 13-18, and subembodiments therein, is 2 and R 9 But R 1 is attached to a ring carbon atom that is meta to the ring carbon attached to R 2 is hydrogen or deuterium, and R 9 is hydrogen, methyl or fluoro.
[0159] 22B. In embodiment 22B, the compounds of embodiment 22A and subembodiments therein, or pharma- ceutically acceptable salts thereof, may comprise R 2 is hydrogen or deuterium, and R 9 is fluoro.
[0160] 22C. In embodiment 22C, the compounds of embodiments 22A and 22B and subembodiments therein, or pharma- ceutically acceptable salts thereof, may comprise R 2a and R 9a is independently hydrogen, deuterium or fluoro, preferably hydrogen or fluoro, more preferably hydrogen.
[0161] 22. In embodiment 22, the compound or pharma- ceutically acceptable salt thereof of any one of embodiments 1A-18 and 22C and subembodiments therein is R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form an oxo. In a first subembodiment of embodiment 22, R 2 and R 9 is R 1is bonded to a ring carbon atom that is meta to the ring carbon bonded to
[0162] 23. In embodiment 23, the compound or pharma- ceutically acceptable salt thereof of any one of embodiments 1A-18 and 22C and subembodiments therein comprises R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkylene. In a first subembodiment of embodiment 23, R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form a cyclopropylene. In a first subembodiment of embodiment 23, R 2 and R 9 is R 1 is bonded to a ring carbon atom that is meta to the ring carbon bonded to
[0163] 24. In embodiment 24, the compound or pharma- ceutically acceptable salt thereof of any one of embodiments 1A-18 and 22C and subembodiments therein comprises R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclylene. In a first subembodiment of embodiment 23, R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form oxetan-4-yl. In a first subembodiment of embodiment 24, R 2 and R 9 is R 1 is bonded to a ring carbon atom that is meta to the ring carbon bonded to
[0164] 25. In embodiment 25, the compound of any one of embodiments 1A to 18 and subembodiments therein, or a pharma- ceutically acceptable salt thereof, is 2 and R 9are attached to the same carbon atom and together with the carbon atom to which they are attached form an alkyldienyl, preferably vinylidienyl. In a first subembodiment of embodiment 22, R 2 and R 9 is R 1 is bonded to a ring carbon atom that is meta to the ring carbon bonded to
[0165] 26. In embodiment 26, the compound of any one of embodiments 1A, 2A, 2Aa, 12A, 13-20 and subembodiments thereof or pharma- ceutically acceptable salts thereof has the formula (VIIIa1) or (VIIIb1): [ka] In one embodiment, the compound has the formula (VIIIb1):
[0166] 27. In embodiment 27, the compound of embodiment 26 and subembodiments therein, or a pharma- ceutically acceptable salt thereof, is R 2 is hydrogen or deuterium, and R 9 is hydrogen, fluoro or methyl, preferably fluoro, and R 2a and R 9a is independently hydrogen, deuterium, or fluoro. In a first subembodiment of embodiment 26, R 2a and R 9a is independently hydrogen or deuterium. In a second subembodiment of embodiment 26, R 2a and R 9a is independently hydrogen or fluoro.
[0167] 28. In embodiment 28, the compound of any one of embodiments 1, 2, 2a, and 12-20 and subembodiments therein, or a pharma- ceutically acceptable salt thereof, has the formula (VIIIa) or (VIIIb): [ka] In one embodiment, the compound has the formula (VIIIb):
[0168] 29. In embodiment 29, the compound of embodiment 28 and subembodiments therein, or a pharma- ceutically acceptable salt thereof, is R 2 is hydrogen, and R 9 is hydrogen, fluoro or methyl.
[0169] 30. In embodiment 30, the compound or pharma- ceutically acceptable salt thereof of any one of embodiments 26 to 29 and subembodiments therein comprises R 7 is hydrogen and R 8 is 3-cyano-5-fluorophenyl or 3-cyano-5-fluoro-2,4,6-trideuteriophenyl.
[0170] It is understood that the above embodiments and subembodiments include all combinations of the embodiments and subembodiments described therein. For example, R 9 may be independently combined with one or more of Embodiments 1A to 30 and / or subembodiments contained therein.
[0171] In further embodiments 40-99, the present disclosure includes the following:
[0172] 40. Formula (IA): [ka] (In the formula, X 1 is CH or N; R 1 are hydroxy, halo, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 , -OCOOR 11 , -OCONR 12 R 13 , -OCHR 14 O.C.O.R. 15 Or -OCHR14 OCOOR 15a where R 10 , R 11 And R 15 and R 15a is independently alkyl or alkyl substituted with amino, carboxy, or hydroxy; R 12 and R 13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxy, or hydroxy, or R 12 and R 13 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl, and each R 14 is hydrogen, alkyl or haloalkyl; R 2 is hydrogen, deuterium, alkyl, halo, haloalkyl, alkenyl, or alkynyl; R 2a is hydrogen or deuterium; R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or R 3 and R 4 together with the carbon to which they are attached form an oxo, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered optionally substituted heterocyclylene; R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy; R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or R 5 and R 6 together with the carbon to which they are attached form an oxo, an alkyldienyl, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered optionally substituted heterocyclylene; with the proviso that R 5 and R 6 And R 3 and R 4do not simultaneously form, together with the carbon to which they are attached, an oxo, a cycloalkylene, or an optionally substituted 4- to 6-membered heterocyclylene; R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl, or haloalkoxy; L is a bond, S, SO, SO2, O, CO or NR 16 where R 16 is hydrogen or alkyl; R 8 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl, where aryl or heteroaryl, respectively by themselves or as part of an aralkyl or heteroaralkyl, or heterocyclyl by itself or as part of a heterocyclylalkyl, is R a , R b , R c , R g and / or R h where R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h is independently selected from hydrogen, deuterium, and halo; and R 9R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, alkylsulfonyl, or heteroaryl, where heteroaryl is independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, and cyano. d , R e and R f optionally substituted with; or R 9 and R 2 are attached to the same carbon atom, they can combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene; R 9a is hydrogen or deuterium) A compound of formula (I) or a pharma- ceutically acceptable salt thereof.
[0173] 41. Formula (I): [ka] (In the formula, X 1 is CH or N; R 1 are hydroxy, halo, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 , -OCOOR 11 , -OCONR 12 R 13 , -OCHR 14 O.C.O.R. 15 Or -OCHR 14 OCOOR 15a where R 10 , R 11 , R 15 and R 15a is independently alkyl or alkyl substituted with amino, carboxy, or hydroxy; R 12 and R 13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxy, or hydroxy, or R12 and R 13 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl, and each R 14 is hydrogen, alkyl or haloalkyl; R 2 is hydrogen, deuterium, alkyl, haloalkyl, alkynyl, or alkenyl; R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or R 3 and R 4 together with the carbon to which they are attached form an oxo, a 3- to 6-membered cycloalkylene, or a 4- to 6-membered optionally substituted heterocyclylene; R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy; R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or R 5 and R 6 together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene or a 4- to 6-membered optionally substituted heterocyclylene; provided that R 5 and R 6 And R 3 and R 4 do not simultaneously form, together with the carbon to which they are attached, a cycloalkylene or an optionally substituted 4- to 6-membered heterocyclylene; R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl, or haloalkoxy; L is a bond, S, SO, SO2, O, CO or NR 16 where R 16 is hydrogen or alkyl; R 8R is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl, where aryl or heteroaryl, each by itself or as part of an aralkyl or heteroaralkyl, or heterocyclyl by itself or as part of a heterocyclylalkyl, is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. a , R b and / or R c is substituted with; and R 9 R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide or alkylsulfonyl, or heteroaryl, where heteroaryl is independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, and cyano. d , R e and R f optionally substituted with; or R 9 and R 2 are attached to the same carbon atom, they can combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene. A compound of formula (I) or a pharma- ceutically acceptable salt thereof.
[0174] 42.R 3 and R 4 is independently halo; or a pharma- ceutically acceptable salt thereof.
[0175] 43.R 3 is halo, and R 4 42. The compound of embodiment 40 or 41, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.
[0176] 44.R 1 is hydroxy; or a pharma- ceutically acceptable salt thereof.
[0177] 45.R 1 or a pharma- ceutically acceptable salt thereof.
[0178] 46.R 6 The compound of any one of embodiments 40-45, or a pharma- ceutically acceptable salt thereof, wherein is halo.
[0179] 47.R 6 is alkyl, preferably R 6 or a pharma- ceutically acceptable salt thereof.
[0180] 48.R 6 or a pharma- ceutically acceptable salt thereof.
[0181] 49.R 6 or a pharma- ceutically acceptable salt thereof.
[0182] 50.R 5
[0081] Embodiment 49. The compound of any one of embodiments 40-49, or a pharma- ceutically acceptable salt thereof, wherein is halo, preferably fluoro.
[0183] 51.R 5 is haloalkyl, preferably R 5or a pharma- ceutically acceptable salt thereof.
[0184] 52.R 5 is alkyl, preferably R 5 is methyl or ethyl; or a pharma- ceutically acceptable salt thereof.
[0185] 53.R 5 The compound of any one of embodiments 40-49, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen or alkoxy.
[0186] 54.R 5 and R 6 or a pharma- ceutically acceptable salt thereof. The compound of any one of embodiments 40-45, wherein, together with the carbon to which they are attached, form a 3-6 membered cycloalkylene, preferably cyclopropylene, cyclobutylene, or cyclopentylene, optionally substituted with one or two fluoro.
[0187] 55.X 1 CR 7 or a pharma- ceutically acceptable salt thereof.
[0188] 56. Formula (IIa1) or (IIb1): [ka] or a pharma- ceutically acceptable salt thereof.
[0189] 57. Formula (IIa1') or (IIb1'): [ka] or a pharma- ceutically acceptable salt thereof.
[0190] 58. Formula (IIa) or (IIb): [ka] or a pharma- ceutically acceptable salt thereof.
[0191] 59. Formula (IIa') or (IIb'): [ka] or a pharma- ceutically acceptable salt thereof.
[0192] 60.Formula (IVa): [ka] (In the formula, R 5 and R 6 together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene, preferably cyclopropylene, cyclobutylene or cyclopentylene, optionally substituted with one or two fluoro. or a pharma- ceutically acceptable salt thereof.
[0193] 61. Formula (VIa) or (VIb): [ka] (In the formula, R 5 and R 6 together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene, preferably cyclopropylene, cyclobutylene or cyclopentylene, optionally substituted with one or two fluoro. or a pharma- ceutically acceptable salt thereof.
[0194] 62. Formula (VIIa) or (VIIb): [ka] or a pharma- ceutically acceptable salt thereof.
[0195] 63.R 3 or a pharma- ceutically acceptable salt thereof.
[0196] 64.R 3 and R 4 or a pharma- ceutically acceptable salt thereof.
[0197] 65. The compound of any one of embodiments 40-64, or a pharma- ceutically acceptable salt thereof, wherein L is O, S, SO, SO2, or NH.
[0198] 66. The compound of embodiment 65, wherein L is O; or a pharma- ceutically acceptable salt thereof.
[0199] 67.R 8 R is cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl, where aryl or heteroaryl, each by itself or as part of an aralkyl or heteroaralkyl, or heterocyclyl by itself or as part of a heterocyclylalkyl, is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. a , R b and R cor a pharma- ceutically acceptable salt thereof.
[0200] 68. The compound of any one of embodiments 40, 42-57, and 63-66 and subembodiments therein, or a pharma- ceutically acceptable salt thereof, comprises R 8 But R a , R b , R c , R g and R h phenyl substituted with, where R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h is independently selected from hydrogen and halo.
[0201] 68A. Embodiment The compound of any one of 40, 42-57, and 63-66 and subembodiments therein, or a pharma- ceutically acceptable salt thereof, may comprise R 8 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methylphenyl Phenyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, 3-cyano-5-difluoromethylphenyl, or 3-cyano-5-fluoro-2,4,6-trideuteriophenyl. In a first subembodiment of embodiment 68A, R 10 is 3-cyano-5-fluorophenyl or 3-cyano-5-fluoro-2,4,6-trideuteriophenyl.
[0202] 69.R 8 R is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. a , R b and R c or a pharma- ceutically acceptable salt thereof.
[0203] 70.R 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl Phenyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, or 3-cyano-5-difluoromethylphenyl, or a pharma- ceutically acceptable salt thereof. 10 is 3-cyano-5-fluorophenyl.
[0204] 71.R 8 or a pharma- ceutically acceptable salt thereof. The compound of any one of embodiments 40-66 and any subembodiments therein, wherein:
[0205] 72.R 8 R is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. a , R b and R c or a pharma- ceutically acceptable salt thereof. The compound of any one of embodiments 40-66 and any subembodiments therein, wherein R is heteroaryl substituted with R;
[0206] 73.R 8 are R a , R b and R cR is a 5- or 6-membered heteroaryl substituted with (e.g., pyridyl, pyridazinyl, pyrimidinyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl or pyrazinyl); a and R b is independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, and cyano, and R c or a pharma- ceutically acceptable salt thereof.
[0207] 74.R 8 is pyridin-3-yl, pyridin-2-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl, pyrimidin-2-yl, thien-2-yl, furan-2-yl, thiazol-5-yl, oxazol-5-yl, imidazol-5-yl, furan-3-yl, thien-3-yl, thiazol-4-yl, pyridin-4-yl, oxazol-2-yl, imidazol-2-yl, pyridin-2-yl, pyrazin-2-yl or thiazol-2-yl, and R a , R b and R c where R a and R b is independently selected from hydrogen, methyl, methoxy, hydroxy, chloro, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy, and R c or a pharma- ceutically acceptable salt thereof. The compound of any one of embodiments 40-66, wherein is selected from hydrogen, methyl, cyano, chloro, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy.
[0208] 75.R 8 is 5-cyanopyridin-3-yl, 5-chloropyridin-3-yl, or 5-fluoropyridin-3-yl; or a pharma- ceutically acceptable salt thereof.
[0209] 76.R7 is hydrogen, methyl, ethyl, methoxy, fluoro, trifluoromethyl or trifluoromethoxy, preferably R 7 The compound of any one of embodiments 40-75, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.
[0210] 77.R 2 or a pharma- ceutically acceptable salt thereof.
[0211] 78.R 9 The compound of any one of embodiments 40-77, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen, alkyl, halo, hydroxy, or alkoxy.
[0212] 79.R 9 The compound of any one of embodiments 40-77, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen, methyl, methoxy, or fluoro.
[0213] 80.R 2 and R 9 The compound of any one of embodiments 40-79, or a pharma- ceutically acceptable salt thereof, wherein: are attached to the same carbon atom.
[0214] 81.R 2 and R 9 is R 1 or a pharma- ceutically acceptable salt thereof.
[0215] 82.R 2 and R 9 and R are attached to the same carbon atom and together with the carbon atom to which they are attached form oxo; or a pharma- ceutically acceptable salt thereof.
[0216] 83.R 2 and R 9are attached to the same carbon atom and together with the carbon atom to which they are attached form a 3-6 membered cycloalkylene; or a pharma- ceutically acceptable salt thereof.
[0217] 84.R 2 and R 9 or a pharma- ceutically acceptable salt thereof. 84. The compound of embodiment 83, wherein: together with the carbon atom to which they are attached, form a cyclopropylene; or a pharma- ceutically acceptable salt thereof.
[0218] 85.R 2 and R 9 or a pharma- ceutically acceptable salt thereof. The compound of any one of embodiments 40-76, wherein: are attached to the same carbon atom and, together with the carbon atom to which they are attached, form a 4-6 membered heterocyclylene; or a pharma- ceutically acceptable salt thereof.
[0219] 85a.R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form an alkyldienyl, preferably vinylidienyl, Embodiment 40 to 76, or a pharma- ceutically acceptable salt thereof.
[0220] 86.R 2 and R 9 is R 1 or a pharma- ceutically acceptable salt thereof.
[0221] 87. The compound of any one of embodiments 40, 42-57, 63-68A, and 71-76, or a pharma- ceutically acceptable salt thereof, is R 2 and R 9 But R 1 is attached to a ring carbon atom that is meta to the ring carbon attached to R 2 is hydrogen or deuterium, and R 9 is hydrogen, methyl or fluoro.
[0222] 88. The compound of embodiment 87 and subembodiments therein, or a pharma- ceutically acceptable salt thereof, comprises R 2 is hydrogen or deuterium, and R 9 is fluoro.
[0223] 89. Formula (VIIIa1) or (VIIIb1): [ka] The compound of any one of embodiments 40, 65-68A, and 71-79, having the structure of: preferably the structure of formula (VIIIb1), or a pharma- ceutically acceptable salt thereof.
[0224] 90.R 2a and R 9a are independently hydrogen or deuterium, preferably R 2a and R 9a is hydrogen; or a pharma- ceutically acceptable salt thereof.
[0225] 91. Formula (VIIIa) or (VIIIb): [ka] The compound of any one of embodiments 41, 65-67, and 69-79, having the structure of: preferably the structure of formula (VIIIb) or a pharma- ceutically acceptable salt thereof.
[0226] 92.R 2 is hydrogen, and R 9 is hydrogen, fluoro, or methyl; or a pharma- ceutically acceptable salt thereof.
[0227] 93. A pharmaceutical composition comprising a compound according to any one of embodiments 40-92 or a pharma- ceutically acceptable salt thereof; and a pharma- ceutically acceptable excipient.
[0228] 94. A method for inhibiting HIF2α, comprising contacting HIF2α with a compound of any one of embodiments 40 to 92 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition of embodiment 93.
[0229] 95. A method of treating a disease mediated by HIF2α in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of any one of embodiments 40-92 or a pharma- ceutical acceptable salt thereof; and a pharma-ceutical acceptable excipient.
[0230] 96. A method of treating cancer in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of any one of embodiments 40-92 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient.
[0231] 97. The method of embodiment 96, wherein the compound of embodiments 40-92 or a pharma- ceutically acceptable salt thereof may be administered, optionally in combination with at least one other anticancer agent.
[0232] 98. The method of embodiment 96 or 97, wherein the cancer is renal carcinoma or glioblastoma.
[0233] 99. The disease is NASH, pulmonary arterial hypertension or inflammatory bowel disease. Embodiment 95 ways.
[0234] Representative disclosed compounds are set forth in Compound Table I below.
[0235] [Table 3]
[0236] [Table 4]
[0237] [Table 5]
[0238] [Table 6]
[0239] [Table 7]
[0240] Additional representative compounds of formula (I) that can be prepared are shown in Table II below.
[0241] [Table 8]
[0242] [Table 9]
[0243] General synthesis scheme The compounds of the present disclosure can be made by the methods depicted in the reaction schemes shown below.
[0244] The starting materials and reagents used in the preparation of these compounds are available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.) or Sigma (St. Louis, Mo.), or are prepared by methods known to those skilled in the art according to procedures described in reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some of the methods by which the compounds of the present disclosure can be synthesized, and various modifications to these schemes can be made and will be suggested to those skilled in the art upon reading this disclosure. The starting materials and intermediates, as well as the end products of the reactions, can be isolated and purified, if necessary, using conventional techniques, including, but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
[0245] Unless specified to the contrary, reactions described herein are carried out at atmospheric pressure over a temperature range of about -78°C to about 150°C, such as about 0°C to about 125°C, and also about room temperature (or ambient temperature), e.g., about 20°C.
[0246] X 1 is CH and R 1 is hydroxyl and R3 , R 4 , R 5 , R 6 , R 7 and R 8 is as defined in the Summary (or any embodiment thereof), and R 9 and R 2 Compounds of formula (I) in which combine to form an alkyldienyl can be prepared as shown and described in Scheme 1 below. [ka]
[0247] R 7 as described in the Summary, and an aldehyde or precursor group thereof of formula 1-a, X 1 is a halide and R 3 For example, a zinc metal mediated Reformatsky reaction between a compound of formula 1-b, where R is independently hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxyalkyl or alkoxyalkyl as defined above, provides a compound of formula 1-c. Compounds of formula 1-a and 1-b are commercially available or can be prepared by methods well known in the art. For example, 2-bromo-4-fluorobenzaldehyde, 2-bromo-2,2-difluoroethyl acetate, 2-bromo-2-methylpropanoate, 2-bromopropanoate, and 2-bromoethyl acetate are commercially available. The hydroxyl group of 1-c can be oxidized under oxidizing conditions such as 2-iodoxybenzoic acid (IBX) or TPAP, NMO, to provide a ketone of formula 1-d. The keto group of a compound of formula 1-d can be functionalized by methods well known in the art to provide a compound of formula 1-e, where R is independently hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxyalkyl or alkoxyalkyl. 5 and R 6 is as described in the overview. For example, R 5 and R 6Compounds of formula 1-e, where is fluoro, can be synthesized from 1-d by treatment with a fluorinating agent such as DAST or SF4 under conditions well known in the art. Cyclization of 1-e can be achieved by treatment with an alkyllithium reagent such as n-BuLi to generate ketone 1-f. The carbonyl group of 1-f can be reduced with a reducing agent such as NaBH4 to give alcohol 1-g.
[0248] Compounds of formula 1-g can be converted to compounds of formula 1-h by lithiation of 1-g followed by treatment of the lithio intermediate with CBr4. Oxidation of 1-h with an oxidizing reagent such as IBX gives the ketones of formula 1-i. Addition of an allyl metal reagent such as allylmagnesium bromide to compounds of formula 1-i gives compounds of formula 1-j.
[0249] Alternatively, compounds of formula 1-j can be prepared from 1-f by adding an allyl metal reagent, such as allylmagnesium bromide, to a compound of formula 1-f shown below. [ka]
[0250] Lithiation of 1-g with a base such as LDA followed by treatment of the lithio intermediate with a brominating reagent such as CBr4 or 1,2-dibromotetrafluoroethane gives compounds of formula 1-j. If desired, enantioselective synthesis of compounds of formula 1-g can be achieved by addition of 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane to compounds of formula 1-f in the presence of a ligand such as 1-m and a suitable base such as tBuONa in an organic solvent such as MeOH, toluene, as shown below. [ka]
[0251] Compounds of formula 1-j can undergo cyclization in the presence of a Pd catalyst with a suitable ligand, such as Pd(dppf)Cl2·CH2Cl2 or Pd(PPh3)2Cl2, to provide compounds of formula 1-k. The fluoro group in compounds of formula 1-k can be obtained by isolating compounds 1-k with the fluoro group in compounds of formula 1-k, where L is N, O or S and R 8 is the formula R defined in the overview 8 -LH compound by treating it with methods well known in the art to obtain L and R 8 Formula -LR is as described in the summary 8 can be converted to a group of formula R 8 The compounds of -LH are commercially available or can be prepared by methods well known in the art. For example, 3-fluoro-5-hydroxybenzonitrile, 3,5-difluorophenol, 3-chloro-5-fluorophenol, 3-chloro-5-hydroxy-benzonitrile, 5-fluoropyridin-3-ol, 5-chloropyridin-3-ol, 5-hydroxynicotinonitrile, 3-fluoro-5-mercaptobenzonitrile, 3-amino-5-fluorobenzonitrile, 3,3-difluorocyclobutan-1-ol, 3-amino-5-fluorobenzonitrile, 3-fluoro-5-mercaptobenzonitrile, 3-chloro-5-mercaptobenzonitrile, 3-amino-5-chlorobenzonitrile are commercially available.
[0252] R 1 is hydroxyl and R 3 , R 4 , R 5 , R 6 , R 7 and R 8 is as defined in the Summary (or any embodiment thereof), and R 9 and R 2 Compounds of formula (I) in which combine to form an oxo can be prepared as shown and described in Scheme 2 below. [ka]
[0253] Compounds of formula 1-k can be converted to compounds of formula 1-l by treatment with oxidative cleavage reagents such as NaIO4 and RuCl3 hydrate under conditions well known in the art. The fluoro group of compounds of formula 1-l can be converted to compounds of formula R 8 By treating with the compound of formula -LH, L and R 8 Formula -LR is as described in the summary 8 can be converted to the group
[0254] Compounds of formula (I) can be converted to other compounds of formula (I) by methods well known in the art. For example, R 1 is hydroxyl and R 2 is hydrogen, and R 9 Compounds of formula (I) where R is hydroxy or fluoro can be further functionalized at the carbonyl group to give R 9 and R 2 can be synthesized from a compound of formula (I) in which
[0255] Method (i) [ka] R 1 is hydroxy and R 9 and R 2 Compounds of formula (I) in which R combines to form an oxo can be converted to R by treatment with a reducing agent such as sodium borohydride under conditions well known in the art. 1 is hydroxy and R 9 can be converted to a compound of formula (I) wherein
[0256] Method (ii) [ka] R 1 is hydroxy and R 9Compounds of formula (I) where R is hydroxy can be converted to R by treatment with a fluorinating agent such as DAST under conditions well known in the art. 1 is hydroxy and R 9 can be converted to a compound of formula (I) where
[0257] utility The compounds disclosed herein are useful for treating HIF-2α mediated diseases, including, but not limited to, various types of cancer, liver diseases such as non-alcoholic steatohepatitis (NASH), inflammatory diseases such as inflammatory bowel disease (IBD), lung diseases such as pulmonary arterial hypertension (PAH), and iron loading disorders.
[0258] HIF-2α plays a key role in the development and progression of many human cancers. Many extensive studies have demonstrated the critical role of increased HIF-2α activity in driving clear cell renal cell carcinoma (ccRCC) (see review by Shen and Kaelin, Seminars in Cancer Biology 23:18-25, 2013). Aberrant HIF-2α activity is mainly due to loss of function of the tumor suppressor VHL. More than 80% of ccRCCs are known to have defective VHL, either by deletion, mutation or impaired post-translational modification. Defective VHL leads to constitutively active HIF-α protein, regardless of oxygen levels. Various studies utilizing gain-of-function and loss-of-function approaches in mouse models have demonstrated that HIF-2α is an important oncogenic substrate of VHL (see Kondo, et al. Cancer Cell 1:237-246, 2002; Kondo, et al. PLoS Biology 1:439-444, 2002; Maranchi, et al. Cancer Cell 1:247-255, 2002; Zimmer, et al. Mol. Cancer Res 2:89-95, 2004). For example, knockdown of HIF-2α in VHL-null tumors inhibited tumor formation, while reintroduction of VHL and overexpression of HIF-2α overcame the tumor suppressive role of VHL. Furthermore, single nucleotide polymorphisms in HIF-2α have been associated with resistance to PHD-mediated degradation and associated with an increased risk of developing RCC. In addition to functioning as a typical tumor-initiating event in ccRCC, the VHL-HIF-2α axis has also been implicated in ccRCC tumor metastasis via its downstream CXCR4 and CYTIP (see Vanharanta et al. Nature Medicine 19:50-59, 2013; Peter Staller et al. Nature. 2003 Sep 18; 425(6955):307-11). Collectively, these studies strongly support the potential therapeutic utility of HIF-2α targeting agents for the treatment of ccRCC.
[0259] Defective VHL predisposes patients to kidney cancer (70% lifetime risk), as well as hemangioblastoma, pheochromocytoma, endolymphatic sac tumors, and pancreatic neuroendocrine tumors. Tumors derived from defective VHL are often driven by constitutively active downstream HIF-α proteins, the majority of which are dependent on HIF-2α activity (see Maher, et al. Eur. J. Hum. Genet. 19:617-623, 2011). Both genetic and epigenetic mechanisms can lead to loss of function of VHL. Epigenetic inactivation of VHL expression, and therefore constitutive activation of HIF-α protein, has been found in many cancers, including RCC, multiple myeloma, retinoblastoma, NSCLC, pancreatic endocrine tumors, squamous cell carcinoma, acute myeloid leukemia, myelodysplastic syndromes, and esophageal squamous cell carcinoma (see review in Nguyen, et al. Arch. Phann. Res 36:252-263, 2013). HIF-2α has also been linked to cancers of the retina, adrenal gland, and pancreas through both loss of function of VHL and activating mutations in HIF-2α. Recently, HIF-2α gain-of-function mutations have been identified in erythrocytosis and paraganglioma with erythrocytosis (see Zhuang, et al. NEJM 367:922-930, 2012; Percy, et al. NEJM 358:162-168, 2008; and Percy, et al. Am. J. Hematol. 87:439-442, 2012). In particular, many of the known HIF-2α target gene products (e.g., VEGF, PDGF and cyclin Dl) have been demonstrated to play important roles in cancers originating from kidney, liver, colon, lung and brain. Therefore, HIF-2α target therapy may be beneficial for the above cancers when triggered by these signaling events downstream of aberrant HIF-2α pathway activation. In addition to loss-of-function of VHL and activating mutations of HIF-2α, HIF-α protein is also frequently upregulated in the intratumoral environment of rapidly growing tumors due to hypoxic conditions resulting from poor vascularization of large tumors. The activated HIF-α pathway then transcriptionally upregulates various essential factors, thereby further promoting tumor cell survival and proliferation.
[0260] Numerous studies have shown a correlation between overexpression of HIF-2α and poor prognosis in various cancers, including astrocytoma, breast, cervical, colorectal, glioblastoma, glioma, head and neck, liver, non-small cell lung, melanoma, neuroblastoma, ovarian and prostate cancers, thereby supporting the pursuit of HIF-2α as a therapeutic target in treating these cancers (see review by Keith, et al. Nature Rev. Cancer 12:9-22, 2012). HIF-2α has been shown to enhance the growth of APC-mutated colorectal cancer through the regulation of genes involved in proliferation, iron utilization and inflammation (see Xue, et al. Cancer Res 72:2285-2293, 2012; and Xue and Shah, Carcinogenesis 32:163-169, 2013). In hepatocellular carcinoma (HCC), knockdown of HIF-2α in preclinical models inhibited cell proliferation in vitro and tumor growth in vivo through downregulation of VEGF and cyclin D 1 (see He, et al. Cancer Sci. 103:528-534, 2012). In NSCLC, approximately 50% of patients show overexpression of HIF-2α protein, which strongly correlates with higher VEGF expression and, more importantly, with shorter overall survival. Interestingly, HIF-1α does not correlate with reduced overall survival in lung cancer patients, even though its expression is also often increased (see Giatromanolaki, et al. Br. J. Cancer 85:881-890, 2001). Extensive studies in engineered mice bearing both non-degradable HIF-2α and mutant KRAS tumors have shown increased tumor burden and decreased survival when compared to mice expressing mutant KRAS alone (see Kim, et al. J. Clin. Invest. 119:2160-2170, 2009). These studies indicate that HIF-2α promotes tumor growth and progression in lung cancer and is negatively correlated with clinical prognosis.
[0261] HIF-2αs activity has been linked to the progression of chronic obstructive pulmonary disease (COPD) in addition to lung cancer in mouse models (see Karoor, et al. Cancer Prev. Res. 5:1061-1071, 2012). HIF-2α activity has also been demonstrated to be important in cancers of the central nervous system (see Holmquist-Mengelbier, et al. Cancer Cell 10:413-423, 2006 and Li, et al. Cancer Cell 15:501-513, 2009). HIF-2α knockdown reduces tumor growth in preclinical animal models of neuroblastoma, and conversely, increased levels of HIF-2α correlate with advanced disease, poor prognosis, and higher VEGF levels, which may contribute to poor clinical outcome. Similarly, higher expression of HIF-2α has been associated with poor survival in gliomas. Experimentally, inhibition of HIF-2α in glioma stem cells reduced cell proliferation and survival in vitro and tumor development in vivo. HIF-1α is expressed in both neural progenitor cells and brain tumor stem cells, whereas HIF-2α is found exclusively in the latter. Furthermore, survival of glioma patients correlates with HIF-2α, but not with HIF-1α levels.
[0262] One of the downstream HIF-2α effectors is cyclin D, which is an essential partner in the activation of CDK4 and CDK6. Thus, administration of HIF-2α inhibitors with CDK4 / 6 inhibitors, including abemaciclib (Verzenio®), palbociclib (Ibrance®), and ribociclib (Kisqali®), should downregulate cyclin D and enhance the antiproliferative effect of CDK4 / 6 inhibitors. A recent study (Nicholson et al Sci Signal. 2019 Oct 1;12(601)) suggests that the antiproliferative effect of CDK4 / 6 inhibition is synergistic with HIF-2α inhibition in HIF-2α-dependent VHL- / - ccRCC cells.
[0263] Radiotherapy, alone or in combination with other therapies, is frequently used in approximately 50% of cancer patients. However, a hypoxic microenvironment within a tumor has long been associated with resistance to radiotherapy. Bhatt and coworkers found that reduced levels of HIF-2α increased the sensitivity of renal cell carcinoma cell lines to ionizing radiation (see Bhatt, et al. BJU Int. 102:358-363, 2008). Furthermore, mechanistic studies by Bertout et al. demonstrated that HIF-2α inhibition enhances the efficacy of radiation through increased p53-dependent apoptosis (see Bertout, et al. PNAS 106:14391-14396, 2009). Thus, HIF-2α targeted therapy may improve response to radiotherapy in various cancers.
[0264] Somatostatinoma is a rare but often malignant neuroendocrine tumor that produces somatostatin. HIF-2α mutations have been found to cause the destruction of the prolyl hydroxylation domain (PHD) of HIF-2α, thus abolishing the modification by PHD and subsequently reducing HIF-2α degradation mediated by VHL (see Yang, et al. Blood. 121:2563-2566, 2013). The stabilized HIF-2α can then translocate to the nucleus and increase the expression of hypoxia-related genes, contributing to somatostatinoma. Thus, HIF-2α inhibitors provide an alternative approach in the treatment of somatostatinoma.
[0265] Polycythemia, also known as erythrocytosis, is a blood disorder characterized by an elevated hematocrit (the volume percentage of red blood cells in the blood). Gain-of-function mutations in HIF-2α are associated with autosomal dominant erythrocytosis (see Percy, et al. N. Engl. J. Med. 358:162-8, 2008 and Wilson et al. Case Rep Hematol. 6373706, 2016). In addition, mutations in the PHD of HIF-2α, which is involved in the signaling of HIF-2α ubiquitination and degradation by VHL, have also been found to cause erythrocytosis. Therefore, HIF-2α inhibitors can suppress HIF-2α downstream genes such as EPO by inhibiting HIF-2αn, which is stabilized by either gain-of-function HIF-2α mutations or loss-of-function mutations in PHD and VHL, which should reduce the hematocrit of erythrocytosis.
[0266] Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors that often arise against a background of predisposing genetic mutations, including loss of function of VHL or PHD2 or activating mutations of HIF-2α, all of which result in high expression of HIF-2α protein and subsequently downstream genes that promote oncogenic progression (see Dahia, Nat Rev Cancer. 14:108-19, 2014). In addition, germline heterozygous mutations in genes encoding succinate dehydrogenase (SDH) subunits and SDH complex assembly factor 2 protein (SDHAF2) have been reported in patients with hereditary pheochromocytoma and paraganglioma (PPGL). These mutations can result in the accumulation of succinate, which leads to the inhibition of prolyl hydroxylases that are essential for mediating ubiquitination / degradation of HIF proteins by the VHL complex. Pituitary adenomas are frequently found to coexist with PPGL. Therefore, inhibition of HIF-2α should be useful for the treatment of both PPGL and pituitary tumors. Mutations in succinate dehydrogenase subunits are also associated with gastrointestinal stromal tumors (GIST), supporting the exploration of HIF-2α inhibitors for the treatment of GIST (see Janeway, et al. Proc. Natl Acad. Sci. USA 108:314-318, 2011).
[0267] Loss-of-function mutations in fumarate hydratase (FH) predispose patients to the autosomal dominant syndrome of cutaneous and uterine leiomyomatosis. Activation of HIF protein has been suggested to contribute to the development of FH-associated tumors by activating the hypoxic pathway. (See O'Flaherty, et al. Hum Mol Genet. 19:3844-3851, 2010 and Wei, et al. J Med Genet. 43:18-27, 2006). In addition, high expression of HIF-2α is found in leiomyosarcoma, a rare neoplasm of smooth muscle origin (See Mayer, et al. Cancer Res. 68:4719, 2008). Thus, inhibition of HIF-2α may be beneficial for the treatment of both leiomyoma and leiomyosarcoma.
[0268] Retinal capillary hemangioblastoma may be an ocular manifestation of VHL disease caused by loss of the tumor suppressor VHL. Upregulation of HIF-2α upon VHL loss has been detected in patients with retinal hemangioblastoma and has been shown to contribute to the aggressive course of retinal hemangioblastoma and result in resistance to multiple anti-VEGF and radiation therapies (see Wang, et al. Graefes Arch. Clin. Exp. Ophthalmol. 252:1319-1327, 2014). Furthermore, uncontrolled vascular growth is a central pathological component of many human visual disorders, including diabetic retinopathy, age-related macular degeneration, glaucoma, and retinopathy of prematurity. Neuronal death and vision loss observed in these diseases are often caused by abnormal leaky blood vessels, a consequence of pathological angiogenesis (see Krock, et al. Genes Cancer. 2:1117-1133, 2011). Considering the causal role of HIF in angiogenesis, inhibitors of HIF-2α may have potential utility in treating various blinding diseases.Indeed, systemic reduction of HIF-2α expression by hypoxic Hif-2α alleles caused a marked reduction in retinal angiogenesis accompanied by defective EPO expression (see Morita, et al. EMBO J.22:1134-46,2003).
[0269] In addition to its direct role in promoting the development, progression, and metastasis of tumor cells (e.g., ccRCC), HIF-2α indirectly contributes to tumorigenesis by enhancing the immunosuppressive effects of hypoxia within the tumor microenvironment. HIF-2α expression has been detected in cells of the myeloid lineage (see Talks KL,et dal.Am J Pathol.2000;157(2):411-421). For example, HIF-2α has been shown to promote the polarization of macrophages into an immunosuppressive M2 phenotype and is essential for the migration and infiltration of tumor-associated macrophages (see Imtiyaz HZ et al.J Clin Invest.2010;120(8):2699-2714). Thus, elevated levels of HIF-2α in tumor-associated macrophages (TAMs) are associated with high-grade human tumors and correlate with poor prognosis. In addition, HIF-2α can indirectly promote additional immunosuppressive pathways (e.g., adenosine and arginase) by regulating the expression of key signaling regulators such as adenosine A2B / A2A receptor and arginase. These data support that HIF-2α is a potential therapeutic target for treating a broader range of inflammatory diseases and cancers, either as a single agent or in combination with other therapeutic agents, such as immunotherapeutic agents.
[0270] Due to the important role of HIF-2α proteins in regulating the physiological response to fluctuations in oxygen levels, they have been implicated in many hypoxia-related pathological processes in addition to cancer. One such disease is PAH, a debilitating and life-threatening disease with a very poor prognosis. Recent studies have shown that HIF-2α contributes to the process of hypoxic pulmonary vascular remodeling, reduced plasticity of the vascular bed, and ultimately debilitating PAH (see Andrew S., et al. Proc Natl Acad Sci USA. 2016 Aug 2; 113(31): 8801-8806; Tang H, et al. Am J Physiol Lung Cell Mol Physiol. 2018 Feb 1; 314(2): L256-L275). These studies provide a new understanding of the role of pulmonary endothelial HIF-2α in regulating pulmonary vascular responses to hypoxia and provide much-needed new therapeutic strategies by targeting HIF-2α. Another example of a pathological process associated with hypoxia is IBD, a chronic recurrent inflammatory disease of the intestine. Intestinal inflammation and subsequent IBD have been found to occur when dysregulated epithelial oxygen tension occurs and intensifies across the intestinal epithelial villi (see Shah YM, Molecular and Cellular Pediatrics, 2016 Dec; 3(1): 1). Activation of HIF-2α contributes to IBD, while HIF-1α in intestinal epithelial cells is considered a major protective factor in IBD (see Karhausen J, et al. J Clin Invest. 2004; 114(8): 1098-1106; Furuta GT, et al. J Exp Med. 2001; 193(9): 1027-1034). Mechanistically, HIF-2α activation not only leads to the upregulation of inflammatory cytokines, directly promoting IBD, but also leads to the loss of intestinal barrier integrity, indirectly contributing to the development of IBD.(See Xue X, et al. Gastroenterology. 2013;145(4):831-841; Glover LE, et al. Proc Natl Acad Sci USA. 2013;110(49):19820-19825.) Thus, HIF-2α inhibitors are expected to reverse the proinflammatory state and enhance the integrity of the intestinal barrier, thereby alleviating the symptoms of IBD.
[0271] HIF-2α inhibitors also represent a novel therapeutic approach for NASH, which has limited available treatment options. Recent studies have shown that gut-specific disruption of HIF-2α leads to a significant reduction in fatty liver and obesity induced by a high-fat diet. Mechanistically, intestinal HIF-2α positively regulates the gene encoding neuraminidase 3, thus regulating ceramide metabolism, which contributes to the development of NASH (see Xie C, et al. Nat Med. 2017 Nov; 23(11): 1298-1308). Therefore, HIF-2α inhibitors should have preventive and therapeutic effects on metabolic disorders such as NASH.
[0272] Several relationships have been identified between HIF-2α levels and iron homeostasis (see Peyssonnaux C et al, Cell Cycle. 2008;7(1):28-32). Several studies have demonstrated a key role for HIF-2α in iron-loading disorders. HIF-2α, but not HIF-1α, has emerged as a key "local" regulator of intestinal iron status through the regulation of various genes important for iron transport and absorption (see Mastrogiannaki M, et al. J Clin Invest. 2009;119(5):1159-1166). Small molecule inhibitors targeting HIF-2α are therefore expected to improve iron homeostasis in patients with iron disorders.
[0273] Thus, the present invention provides methods for treating or reducing the severity of a disease, condition, or disorder in which activation or overactivation of HIF-2α is implicated in the pathology. In another aspect, the disclosure provides a method of treating renal cell carcinoma in a subject with a compound disclosed herein or a pharma- ceutically acceptable salt thereof.
[0274] HIF-2α inhibitors also have therapeutic potential for a wide range of non-cancer indications, including but not limited to NASH, IBD, PAH and iron overload.
[0275] test The HIF2α inhibitory activity of compounds of the present disclosure can be tested using the in vitro assay described in Biological Example 1 below.
[0276] Pharmaceutical Compositions In general, the compounds of the present disclosure are administered in a therapeutically effective amount by any of the accepted administration methods for agents providing similar utilities. The therapeutically effective amount of the compounds of the present disclosure may range from about 0.01 to about 500 mg per kg of patient body weight per day, which may be administered in single or multiple doses. Suitable dosage levels may be from about 0.1 to about 250 mg / kg per day; from about 0.5 to about 100 mg / kg per day. Suitable dosage levels may be from about 0.01 to about 250 mg / kg per day, from about 0.05 to about 100 mg / kg per day, or from about 0.1 to about 50 mg / kg per day. Within this range, dosages may be from about 0.05 to about 0.5, from about 0.5 to about 5, or from about 5 to about 50 mg / kg per day. For oral administration, the composition can be provided in the form of a tablet containing about 1.0 to about 1000 milligrams of active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of active ingredient. The actual amount of the compound of the present disclosure, i.e., active ingredient, will depend on many factors, such as the severity of the disease being treated, the age and relative health of the patient, the potency of the compound utilized, the route and form of administration, and other factors.
[0277] In general, the compounds of the present disclosure are administered as pharmaceutical compositions by any of the following routes: oral, systemic (e.g., transdermal, intranasal or suppository) or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred method of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of affliction. The composition can take the form of a tablet, pill, capsule, semisolid, powder, sustained release formulation, solution, suspension, elixir, aerosol or other suitable composition.
[0278] The choice of formulation depends on various factors, such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules, with pills or capsules containing enteric coatings or delayed release tablets being preferred) and the bioavailability of the drug substance.
[0279] The composition generally comprises the compound of the present disclosure combined with at least one pharma-ceutically acceptable excipient.Acceptable excipient is non-toxic, aids administration, and does not adversely affect the therapeutic benefits of the compound of the present disclosure.Such excipient can be any solid, liquid, semi-solid, or gaseous excipient that is generally available to those skilled in the art in the case of aerosol compositions.
[0280] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, etc. Liquid and semi-solid excipients may be selected from glycerol, propylene glycol, water, ethanol, and various oils including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, preferably particularly for injectable solutions, include water, saline, aqueous dextrose and glycols.
[0281] The compounds can be formulated for parenteral administration by injection, for example, bolus injection or continuous infusion. The preparations for injection can be provided in unit dosage form, for example, in ampoules or multi-dose containers, with the addition of preservatives. The compositions can take the form of suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain compounding agents, such as suspending, stabilizing and / or dispersing agents. The preparations can be provided in unit dosage or multi-dose containers, for example, sealed ampoules and vials, and can be stored in powder form or freeze-dried (lyophilized) condition, requiring only the addition of a sterile liquid carrier, for example, physiological saline or sterile pyrogen-free water immediately before use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the kind previously described.
[0282] Preparations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compound, which may contain antioxidants, buffers, bacteriostats, and solutes that render the preparation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compound, allowing for the preparation of highly concentrated solutions.
[0283] In addition to the above-mentioned formulations, the compound can also be formulated as a depot preparation.Such long-acting preparations can be administered by implantation (for example, subcutaneous or intramuscular) or intramuscular injection.Thus, for example, the compound can be formulated with suitable polymer or hydrophobic materials (for example, as an emulsion in acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as sparingly soluble salts.
[0284] For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in a conventional manner.Such compositions may contain the active ingredient in a flavor base, such as sucrose and acacia or tragacanth.
[0285] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter, polyethylene glycol or other glycerides.
[0286] Certain compounds disclosed herein may be administered by local administration, i.e., non-systemic administration. This includes application of the compounds disclosed herein to the outside of the epidermis or buccal cavity, and instillation of such compounds into the ears, eyes, and nose, such that the compounds do not significantly enter the bloodstream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal, and intramuscular administration.
[0287] Formulations suitable for topical administration include liquid or semi-liquid formulations suitable for penetration through the skin to the site of inflammation, such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, 0.001% to 10% w / w (weight) of the formulation. In certain embodiments, the active ingredient may comprise up to 10% w / w. In other embodiments, this may comprise less than 5% w / w. In certain embodiments, the active ingredient may comprise 2% w / w to 5% w / w. In other embodiments, this may comprise 0.1% to 1% w / w of the formulation.
[0288] For administration by inhalation, the compound can be conveniently delivered from an insufflator, a nebulizer pressurized pack or other convenient means of delivering an aerosol spray. The pressurized pack can contain a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the unit of dosage can be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compound according to the present disclosure can take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base, such as lactose or starch. The powder composition can be presented in unit dosage form, for example in capsules, cartridges, gelatin or blister packs, from which the powder can be administered with the aid of an inhaler or insufflator. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by EW Martin (Mack Publishing Company, 20th ed., 2000).
[0289] The level of the compound in the formulation can vary within the full range used by those skilled in the art. Typically, the formulation contains, on a weight percent (wt%) basis, about 0.01-99.99% by weight of the compound of the present disclosure based on the total formulation, with the remainder being one or more suitable pharmaceutical excipients. For example, the compound is present at a level of about 1-80% by weight.
[0290] Combinations and Combination Therapies The compounds of the present disclosure may be used in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present disclosure or other drugs may be useful. Such other drugs may be administered simultaneously or sequentially with the compounds of the present disclosure by a route and in an amount commonly used thereby. When the compounds of the present disclosure are used simultaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compounds of the present disclosure is preferred. However, combination therapy may also include therapy in which the compounds of the present disclosure and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present disclosure and the other active ingredients may be used in lower doses than when each is used alone.
[0291] Accordingly, the pharmaceutical compositions of the present disclosure include those that contain one or more other drugs, in addition to a compound of the present disclosure.
[0292] The above combinations include not only combinations of the compounds of the present disclosure with one other drug, but also combinations with two or more other active drugs. Similarly, the compounds of the present disclosure may be used in combination with other drugs used to prevent, treat, control, improve or reduce the risk of a disease or condition for which the compounds of the present disclosure are useful. Such other drugs may be administered simultaneously or sequentially with the compounds of the present disclosure by a route and in an amount commonly used thereby. When the compounds of the present disclosure are used simultaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compounds of the present disclosure may be used. Thus, the pharmaceutical compositions of the present disclosure also include those that contain one or more other active ingredients in addition to the compounds of the present disclosure. The weight ratio of the compounds of the present disclosure to the second active ingredient may vary and depends on the effective dose of each ingredient. Generally, an effective dose of each is used.
[0293] If a subject in need is suffering from or at risk of suffering from cancer, the subject can be treated with the compounds of the present disclosure in any combination with one or more other anti-cancer agents. In some embodiments, the one or more anti-cancer agents are pro-apoptotic agents. Examples of anti-cancer agents include: gossyphol, genasense, polyphenol E, chlorofusin, all-trans retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all-trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec™), geldanamycin, 17-N-allylamino These include, but are not limited to, -17-demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY11-7082, PKC412 or PD184352, Taxol™, also known as "paclitaxel", which is a well-known anti-cancer drug that acts by enhancing and stabilizing microtubule formation, and any of its analogs such as Taxol™, Taxotere™. Compounds that share the basic taxane backbone as a common structural feature have also been shown to have the ability to arrest cells in the G2-M phase with stabilized microtubules, and may be useful in combination with the compounds described herein to treat cancer.
[0294] Suitable anti-cancer agents also include inhibitors of kinases associated with cell proliferation disorders, including, but not limited to, Aurora-A, BTK, CDK1, CDK2, CDK3, CDK4, CDK6, CDK5, CDK7, CDK8, CDK9, ephrin receptor kinase, CHK1, CHK2, SRC, Yes, Fyn, Lck, Fer, Fes, Syk, Itk, Bmx, GSK3, JNK, MEK, PAK1, PAK2, PAK3, PAK4, PDK1, PKA, PKC, RAF, Rsk, and SGK.In particular, inhibitors of CDK4 / 6, including abemaciclib (Verzenio), palbociclib (Ibrance), and ribociclib (Kisqali), which have shown synergy with HIF-2α inhibitors and the potential to reverse resistance to HIF-2α inhibition; inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, S P600125, BAY43-9006, wortmannin or LY294002; Syk inhibitors; antibodies (e.g., Rituxan); MET inhibitors such as foretinib, carbozantinib or crizotinib; VEGFR inhibitors such as sunitinib, sorafenib, regorafenib, lenvatinib, vandetanib, carbozantinib, axitinib; afatinib, brivanib, carbozatinib, erlotinib, gefitinib, neratinib, lapatinib, EGFR inhibitors such as nibs; XL147, XL765, BKM120 (buparlisib), GDC-0941, BYL719, IPI145, BAY80-6946. PI3K inhibitors such as BEX235 (dactolisib), CAL101 (idelalisib), GSK2636771, TG100-115; rapamycin (sirolimus), temsirolimus, everolimus, XL388, XL765, AZD2013, PF04691502, MTOR inhibitors such as PKI-587, BEZ235, GDC0349; MEK inhibitors such as AZD6244, trametinib, PD184352, pimasertinib, GDC-0973, AZD8330; CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-054, RG7155, etc.); TGF beta receptor kinase inhibitors such as LY2157299; and BTK inhibitors such as ibrutinib.
[0295] Other anti-cancer drugs include proteasome inhibitors such as carfilzomib, MLN9708, delanzomib or bortezomib; BET inhibitors such as INCB054329, OTX015, CPI-0610; LSD1 inhibitors such as GSK2979552, INCB059872; HDAC inhibitors such as panobinostat, vorinostat; DNA methyltransferase inhibitors and other epigenetic modulators such as azacytidine, decitabine; SHP-2 inhibitors such as TNO155; Bcl2 inhibitor ABT-199 and other Bcl-2 family protein inhibitors; HIF-2α inhibitors such as PT2977 and PT2385; beta-catenin pathway inhibitors, notch pathway inhibitors and hedgehog pathway inhibitors. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept.
[0296] Other anti-cancer agents / drugs that can be used in combination with the compounds of the present invention include, but are not limited to, Liver X Receptor (LXR) modulators, including LXR agonists and LXR beta selective agonists; aryl hydrocarbon receptor (AhR) inhibitors.
[0297] Other anti-cancer agents that can be used in combination with the compounds of the present disclosure include adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adzelesin; aldesleukin; altretamine; ambomycin; amethanthrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; visna Fisidodimesylate;Bizelesin;Bleomycin sulfate;Brequinar sodium;Bropirimine;Busulfan;Cactinomycin;Calsterone;Caracemide;Carbetimer;Carboplatin;Carmustine;Carubicin hydrochloride;Carzelesin;Cedefingol;Chlorambucil;Cladribine;Cladribine;Crisnatol mesylate;Cyclophosphamide;Cytarabine;Dacarbazine;Daunorubicin hydrochloride;Decitabine;Dexorumaplatin;Desaguanine;Desaguanine mesylate;Diaziquone;Doxorubicin;Doxorubicin hydrochloride;Droloquinoline Cifen;Droloxifene citrate;Drotestosterone propionate;Duazomycin;Edatrexate;Eflornithine hydrochloride;Elsamitrucin;Enloplatin;Enpromate;Epipropizine;Epirubicin hydrochloride;Elbrozole;Esorubicin hydrochloride;Estramustine;Estramustine-Estramustine phosphate sodium;Etanidazole;Etoposide;Etoposide phosphate;Etoprine;Fadrozole hydrochloride;Fazarabine;Fenretinide;Floxuridine;Fludarabine phosphate;Fluorouracil;Flurocitabine; Foskidon;Fostriesin sodium;Gemcitabine;Gemcitabine hydrochloride;Urea hydroxide;Idarubicin hydrochloride;Ifosfamide;Irmofosine;Interleukin II (including recombinant interleukin or Ril2);Interferon alpha-2a;Interferon alpha-2b;Interferon alpha-n1;Interferon alpha-n3;Interferon beta-1a;Interferon gamma-1b;Iproplatin;Irinotecan hydrochloride;Lanreotide acetate;Letrozole;Leuprolide acetate;Liarozole hydrochloride;Lometrexol sodium;Lomustine;Rosoxantrone hydrochloride; Masoprocol; Maytansine; Mechlorethamine hydrochloride; Megestrol acetate; Melengestrol acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate sodium; Metoprine; Meturedepa; Mitindomide; Mitocalcin; Mitochromine; Mitodiline; Mitomarcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone hydrochloride; Mycophenolic acid; Nocodazole; Nogalamycin; O Lumaplatin;Oxisuran;Pegaspargase;Periomycin;Pentamustine;Peplomycin sulfate;Perfosfamide;Pipobroman;Piposulfan;Piroxantrone hydrochloride;Plicamycin;Promestane;Porfimer sodium;Porfiromycin;Prednimustine;Procarbazine hydrochloride;Puromycin;Puromycin hydrochloride;Pyrazofurin;Riboprin;Rogletimide;Safingol;Safingol hydrochloride;Semustine; Simtrezen;Sparfosate sodium;Sparsomycin;Spirogermanium hydrochloride;Spiromustine;Spiroplatin;Streptonigrin;Streptozocin;Sulofenur;Tallysomycin;Tecogalan sodium;Tegafur;Teroxantrone hydrochloride;Temoporfin;Teniposide;Teroxylon;Testolactone;Thiamiprine;Thioguanine;Thiotepa;Tiazofurin;Tirapazamine;Toremifene citrate;Trestron acetate;Triciribine These include: vinphosfate; trimetrexate; trimetrexate glucuronide; triptorelin; tuburozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglicinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrocidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride;
[0298] Other anti-cancer agents that can be used in combination with the compounds of the present disclosure include 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adzelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsal morphogenetic protein 1; antiandrogens, prostate cancer; antiestrogens; antitumor drugs; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modifiers; apoptosis regulators; apurinic acid ara-CDP-DL-PTBA; apurinic acid Arginine deaminase;Aslaculin;Atamestane;Atrimustine;Axinastatin 1;Axinastatin 2;Axinastatin 3;Azasetron;Azatoxin;Azatyrosine;Baccatin III derivatives;Balanol;Batimastat;BCR / ABL antagonists;Benzochlorins;Benzoylstaurosporine;β-Lactam derivatives;β-Aretin;Betaclamycin B;Betulinic acid;Bfgf inhibitors;Bicalutamide;Bisantrene;Bisaziridinylspermine;Bisnafide;Bistratin A;Bizelesin;Brefurate;Bropirimine;Budotitanium;Buthionine sulfoximine;Calcipotriol;Calfostin C;Camptothecin derivatives;Canarypox IL-2;Capecitabine;Carboxamido-amino-triazoles;Carboxamidotriazoles;CaRest M3;CARN 700;cartilage-derived inhibitor;carzelesin;casein kinase inhibitor (ICOS);castanospermine;cecropin B;cetrorelix;chlorln;chloroquinoxaline sulfonamide;cicaprost;cis-porphyrin;cladribine;clomiphene analogues;clotrimazole;collismycin A;collismycin B;combretastatin A4;combretastatin analogues;conagenin;crambescidin 816;crisnatol;cryptophycin 8;cryptophycin A derivatives;curacin A;cyclopentathraquinone;cycloplatam;sipemycin;Cytarabine ocphosphate;Cytolytic factors;Cytostatin;Dacliximab;Decitabine;Dehydrodidemnin B;Deslorelin;Dexamethasone;Dexyphosphamide;Dexrazoxane;Dexverapamil;Diaziquone;Didemnin B;Didox;Diethylnorspermine;Dihydro-5-azacytidine;9-dioxamycin;Diphenylspiromustine;Docosanol;Dolasetron;Doxifluridine;Droloxifene;Dronabinol;Duocarmycin SA;Ebselen;Ecomustine;Edelfosine;Edreco Lomab;Eflomitin;Elemene;Emiteflu;Epirubicin;Epristeride;Estramustine analogs;Estrogen agonists;Estrogen antagonists;Etanidazole;Etoposide phosphate;Exemestane;Fadrozole;Fazarabine;Fenretinide;Filgrastim;Finasteride;Flavopiridol;Flezelastine;Fluasterone;Fludarabine;Fluorodaunornithine hydrochloride;Forfenimex;Formestane;Fostriecin;Fotemustine;Gadolinium texaphyrin;Gallium nitrate;Galocitabine; Ganirelix;gelatinase inhibitors;gemcitabine;glutathione inhibitors;hepsulfame;heregulin;hexamethylene bisacetamide;hypericin;ibandronate;idarubicin;idoxifene;idramantone;ilmofosine;ilomastat;imidazoacridone;imiquimod;immunostimulating peptides;insulin-like growth factor-1 receptor inhibitors;interferon agonists;interferon;interleukin;iobenguane;iododoxorubicin;ipomeanol, 4-;iropract;irsogladine;isobengazole;isohomo Halichondrin B;Itasetron;Jasplakinolide;Kahalalide F;Lamellarin-N triacetate;Lanreotide;Leinamycin;Lenograstim;Lentinan sulfate;Leptolstatin;Letrozole;Leukemia inhibitory factor;Leukocyte alpha interferon;Leuprolide + estrogen + progesterone;Leuprorelin;Levamisole;Liarozole;Linear polyamine analogues;Lipophilic disaccharide peptides;Lysoclinamide 7;Lobplatin;Lombricin;Lometrexol;Lonidamine;Losoxantrone;Loxoribine;Raltotecan;Lutetium texaphyrin;Lysofylline;Cytolytic peptides;Maytansine;Mannostatin A;Marimastat;Masoprocol;Maspin;Matrilysine inhibitors;Matrix metalloproteinase inhibitors;Menogaril;Melbarone;Meterelin;Methioninase;Metoclopramide;MIF inhibitors;Mifepristone;Miltefosine;Mirimostim;Mismatched double-stranded RNA;Mitoguazone;Mitolactol;Mitomycin analogues;Mitonafide;Mitotoxin fibroblast growth factor-saporin;Mitoxantrone;Mofalotene;Molgramostim;Monoclonal antibodies, human chorionic gonadotropin;Mopida Mol; multidrug resistance gene inhibitors; multiple tumor suppressor 1-based therapeutics; mustard anticancer agents; mycaperoxide B; mycobacterial cell wall extracts; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagressip; naloxone + pentazocine; napavine; naphterpine; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide regulators; nitroxide antioxidants; nitrullyn; O6-benzylguanine; octreotide; oxenone; oligonucleotides; onapristone; ondansetron; ;Orasin;Oral cytokine inducers;Ormaplatin;Osateron;Oxaliplatin;Oxaunomycin;Palauamine;Palmitoyl rhizoxin;Pamidronic acid;Panaxytriol;Panomyphen;Parabactin;Pazeliptin;Pegaspargase;Perdecin;Pentosan polysulfate sodium;Pentostatin;Pentrozole;Perflubron;Perphosphamide;Perillyl alcohol;Phenazinomycin;Phenylacetic acid;Phosphatase inhibitors;Picibanil;Pilocarpine hydrochloride;Pirarubicin;Piritrexim;Plasetin A;Plasetin B;Plasminogen activator inhibitors;Platinum complexes;Platinum compounds;Platinum-triamine complexes; Porfimer sodium;Porfiromycin;Prednisone;Propyl bis-acridone;Prostaglandin J2;Proteasome inhibitors;Protein A-based immunomodulators;Protein kinase C inhibitors;Microalgae;Protein tyrosine phosphatase inhibitors;Purine nucleoside phosphorylase inhibitors;Purpurin;Pyrazoloacridines;Pyridoxylated hemoglobin polyoxyethylene conjugates;raf antagonists;Raltitrexed;Ramosetron;Ras farnesyl protein transferase inhibitors;Ras inhibitors;Ras-GAP inhibitors;Demethylated reterliptin;Rhenium etidronate Re186;Rhizoxin;Ribozymes;R 11Retinamide;Rohitukin;Romurtide;Rokinimex;Rubiginone B1;Ruboxil;Safingol;Saintopin;SarCNU;Sarcophytol A;Sargramostim;Sdi1 mimetic;Semustine;Senescence derived 1;Sense oligonucleotide;Signal transduction inhibitors;Signal transduction modulators;Single-chain antigen binding protein;Schizofuran;Sobuzoxane;Sodium borocaptate;Sodium phenylacetate;Sorberol;Somatomedin binding protein;Sonermin ;Sparfosic acid;Spicamycin D;Spiromustine;Splenopentin;Spongistatin 1;Squalamine;Stem cell inhibitors;Stem cell division inhibitors;Stipiamide;Stromelysin inhibitors;Sulfinosine;Superactive vasoactive intestinal peptide antagonists;Sladista;Suramin;Swainsonine;Synthetic glycosaminoglycans;Talimustine;Tamoxifen methiodide;Tauromustine;Tazarotene;Tecogalan sodium;Tegafur;Terlapyrylium;Telomerase inhibitors;Temopo Lupin;Temozolomide;Teniposide;Tetrachlorodecaoxide;Tetrazomine;Taliblastine;Thiocoraline;Thrombopoietin;Thrombopoietin mimetics;Thymalfasin;Thymopoietin receptor agonists;Thymotrin;Thyroid-stimulating hormone;Tin ethyl etiopurpurin;Tirapazamine;Titanocene dichloride;Topsentin;Toremifene;Pluripotent stem cell factor;Translation inhibitors;Tretinoin;Triacetyluridine;Triciribine;Trimetrexate;Triptorelin;Tropicetro These include: turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector systems, red blood cell gene therapy agents; veraresol; veramine; verudin; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
[0299] Still other anti-cancer agents that can be used in combination with the compounds of the present disclosure include alkylating agents, antimetabolites, natural products or hormones, such as nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkylsulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, etc.) or triazenes (e.g., decarbazine, etc.). Examples of antimetabolites include, but are not limited to, folic acid analogs (e.g., methotrexate) or pyrimidine analogs (e.g., cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[0300] Examples of useful natural products to combine with the compounds of the present disclosure include, but are not limited to, vinca alkaloids (e.g., vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
[0301] Examples of alkylating agents that can be used in combination with the compounds of the present disclosure include, but are not limited to, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethylenimines and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkylsulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.) or triazenes (e.g., decarbazine, etc.). Examples of antimetabolites include, but are not limited to, folic acid analogs (e.g., methotrexate) or pyrimidine analogs (e.g., fluorouracil, floxuridine, cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[0302] Examples of hormones and antagonists useful in combination with the compounds of the present disclosure include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogens (e.g., flutamide), gonadotropin-releasing hormone analogs (e.g., leuprolide). Other agents that can be used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboplatin), anthracenediones (e.g., mitoxantrone), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), adrenal cortical suppressants (e.g., mitotane, aminoglutethimide).
[0303] Other anti-cancer agents that can be used in combination with the compounds of the present disclosure include elbrozole (also known as R-55104), dolastatin 10 (also known as DLS-10 and NSC-376128), mibobulin isethionate (also known as CI-980), vincristine, NSC-639829, discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtin (including Altorhyrtin A and Altorhyrtin C), spongistatin, and the like. spongistatin 1, spongistatin 2, spongistatin 3, spongistatin 4, spongistatin 5, spongistatin 6, spongistatin 7, spongistatin 8, spongistatin 9, etc., cemadotin hydrochloride (also known as LU-103793 and NSC-D-669356), epothilones (epothilone A, epothilone B, epothilone C (also known as desoxyepothilone A or dEpoA), epothilone D (also known as KOS-862, dEpoB and desoxyepothilone B), epothilone E, epothilone F, epothilone B N-oxide, epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21-hydroxyepothilone D (also known as desoxyepothilone F and dEpoF), 26-fluoroepothilone), auristatin PE (also known as NSC-654663), sobridotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), L S-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy ofSciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651), SAH-49960 (Lilly / Novartis), SDZ-268970 (Lilly / Novartis), AM-97 (Armad / Kyowa Hakko), AM-132 (Armad), AM-138 (Armad / Kyowa Hakko), IDN-5005 (Indena), cryptophycin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCl and RPR-258062A), bitilebamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (also known as Tularik, T-67, TL-138067, TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B. Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton / Mt. Sinai School of Medicine) Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterin, 3-BAABU (Cytoskeleton / Mt. Sinai School of Medicine, also known as MF-191), TMPN (Arizona StateUniversity), vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, inanosin (also known as NSC-698666), 3-1AABE (Cytoskeleton / Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, also known as T-900607), RPR-115781 (Aventis), eleutherobin (desmethyleleutherobin, desacetyleleutherobin, isoeleutherobin A, Z-eleutherobin, etc.), caribeoside, caribeolin, halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), diozostatin, (-)-phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Anticancer drugs that act by arresting cells in the G2-M phase with stabilized microtubules include: Myoseverin B, D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), resbelostatin sodium phosphate, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).
[0304] One or more additional immune checkpoint inhibitors can be used in combination with the compounds described herein for the treatment of HIF-2α-related diseases, disorders, or conditions. Exemplary immune checkpoint inhibitors include inhibitors (sumac molecules or biologics) against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD39, CD47, OX40, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, SHP-2, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1, and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, CD137, and STING. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors, and TGFR beta inhibitors.
[0305] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.
[0306] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).
[0307] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK-4166, INCAGN01876 or MK-1248. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of OX40, such as an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562 or INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600, or LAG 525. In some embodiments, the OX40L fusion protein is MEDI6383.
[0308] The compounds of the present invention can also be used to increase or enhance immune responses, including increasing immune responses to antigens; improve immunization, including increasing vaccine efficacy; and increase inflammation. In some embodiments, the compounds of the present invention can be used to enhance immune responses to vaccines, including, but not limited to, Listeria vaccines, oncolytic virus vaccines, and cancer vaccines such as GVAX® (a tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CF) gene). Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines, and recombinant viruses. Other immunomodulatory agents include those that block immune cell migration, such as antagonists against chemokine receptors, including CCR2 and CCR4; Sting agonists, and Toll receptor agonists.
[0309] Other anti-cancer agents include those that enhance the immune system, such as adjuvants or adoptive T cell transfer. The compounds of the present application may be effective in combination with CAR (chimeric antigen receptor) T cell treatment as a booster of T cell activation. EXAMPLES
[0310] The following preparations of compounds of formula (IA) / (I) are given to enable those skilled in the art to more clearly understand and to practice the present disclosure, and should not be considered as limiting the scope of the disclosure, but merely as illustrative and representative thereof.
[0311] Example 1 Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] Step 1: Ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-hydroxypropanoate [ka] To a stirred mixture of zinc (6.97 g, 106.56 mmol, 1.03 equiv), 1,2-dibromoethane (388.71 mg, 2.069 mmol, 0.02 equiv) and chlorotrimethylsilane (1.12 g, 10.31 mmol, 0.10 equiv) in THF (200 mL) was added a solution of 2-bromo-2,2-difluoroethyl acetate (21.0 g, 103.45 mmol, 1.0 equiv) and 2-bromo-4-fluorobenzaldehyde (21.0 g, 103.45 mmol, 1.0 equiv) in THF (100 mL) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 75° C. for 16 h under nitrogen atmosphere. The reaction was cooled and quenched with ice / water. The organic solvent was removed under vacuum and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EtOAc (5:1) to give the title compound (18 g, 53.2%) as a yellow oil.
[0312] Step 2: Ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-oxopropanoate [ka] To a stirred solution of ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-hydroxypropanoate (16 g, 48.9 mmol, 1.0 equiv) in CH3CN (200 mL) was added 2-iodoxybenzoic acid (27.4 g, 97.83 mmol, 2.0 equiv) at room temperature, and the resulting mixture was stirred at 80° C. for 3 h. The reaction solution was then cooled to room temperature, filtered, and the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (10:1) to give the title compound (10.3 g, 64.8%) as a yellow oil.
[0313] Step 3: Ethyl 3-(2-bromo-4-fluorophenyl)-2,2,3,3-tetrafluoropropanoate [ka] To a stirred solution of ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-oxopropanoate (6.1 g, 18.8 mmol, 1.0 equiv) in CHCl3 (6 mL) was added DAST (30.25 g, 187.6 mmol, 10.0 equiv) dropwise at room temperature, and the resulting mixture was stirred at 70° C. for 16 h under nitrogen atmosphere. The reaction solution was cooled to room temperature and quenched with ice / water. The mixture was extracted with DCM. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (10:1) to give the title compound (2.4 g, 36.8%) as a yellow oil.
[0314] Step 4: 2,2,3,3,6-Pentafluoro-2,3-dihydro-1H-inden-1-one [ka] To a stirred solution of ethyl 3-(2-bromo-4-fluorophenyl)-2,2,3,3-tetrafluoropropanoate (4.20 g, 12.10 mmol, 1.0 equiv) in THF (50 mL) was added n-BuLi (2.5 M, 7.26 mL, 18.15 mmol, 1.5 equiv) dropwise at −78° C. under nitrogen atmosphere, and the resulting mixture was stirred between −70° C. and −80° C. under nitrogen atmosphere for 2 h. The reaction was quenched with saturated aqueous NH4Cl solution and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (20:1) to give the title compound (2.25 g, 83.7%).
[0315] Step 5: 2,2,3,3,6-Pentafluoro-2,3-dihydro-1H-inden-1-ol [ka] To a stirred solution of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (300 mg, 1.35 mmol, 1.0 equiv) and triethylamine (273.35 mg, 2.70 mmol, 2.0 equiv) in DCM (3 mL) was added formic acid (186.49 mg, 4.05 mmol, 3.0 equiv) dropwise at 0° C., followed by the addition of RuCl(P-cymene)[(S,S)-Ts-DPEN] (8.59 mg, 0.014 mmol, 0.01 equiv). The resulting mixture was stirred at room temperature under nitrogen atmosphere for 3 h and then washed with water. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (300 mg, 99.1%).
[0316] Step 6: 7-Bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol [ka] To a stirred solution of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (2500 mg, 11.154 mmol, 1.00 equiv) in tetrahydrofuran (60 mL) was added LDA (2.0 M, 16.73 mL, 33.463 mmol, 3.00 equiv) dropwise at −78° C. under nitrogen atmosphere. The resulting mixture was warmed to −30° C. over 30 min and stirred at −30° C. for an additional 30 min. To the above mixture was added a THF solution of carbon tetrabromide (3699.05 mg, 11.154 mmol, 1.00 equiv) dropwise at −78° C. The resulting mixture was warmed to −30° C. over 30 min and stirred at −30° C. for an additional 30 min. The reaction was quenched with saturated aqueous NH4Cl at −30° C. The resulting mixture was extracted with EtOAc, and the organic layer was washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EtOAc (10:1) to give the title compound (2600 mg, 76.9%) as a pale yellow oil. MS (ES, m / z): [MH] - =300.9,302.9.
[0317] Step 7: 7-Bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one [ka] To a stirred mixture of 7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (2.63 g, 8.679 mmol, 1.00 equiv) in CH3CN (45 mL) was added IBX (4.86 g, 17.356 mmol, 2.00 equiv) at room temperature. The resulting mixture was stirred at 80°C for 3 h, then cooled and filtered. The filter cake was washed with EtOAc. The combined filtrates were concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (10:1) to give the title compound (1.8 g, 68.9%) as an off-white solid.
[0318] Step 8: 1-Allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol [ka] To a stirred solution of 7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (100 mg, 0.332 mmol, 1.00 equiv) in THF (3 mL) was added allylmagnesium bromide (1.0 M, 0.50 mL, 0.50 mmol, 1.50 equiv) dropwise at −78° C. under nitrogen atmosphere. The resulting mixture was stirred at −78° C. for 1 h under nitrogen atmosphere. The reaction was quenched with saturated aqueous NH4Cl solution. The resulting mixture was extracted with EtOAc and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (90 mg, 79.0%) as a yellow oil. MS (ES, m / z): [MH] - =340.9,342.9.
[0319] Step 9: 3,3,4,4,7-Pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol [ka] To a stirred mixture of 1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (1050 mg, 3.060 mmol, 1.00 equiv) in DMF (25 mL) was added AcONa (753.17 mg, 9.181 mmol, 3.00 equiv) and Pd(dppf)Cl2·CH2Cl2 (249.93 mg, 0.306 mmol, 0.10 equiv) at room temperature. The resulting mixture was stirred at 100 °C under nitrogen atmosphere for 3 h. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (370 mg, 46.1%) as a pale yellow oil.
[0320] Step 10: 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred mixture of 3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol (40 mg, 0.15 mmol, 1.00 equiv.) and 3-fluoro-5-hydroxybenzonitrile (20.92 mg, 0.153 mmol, 1.00 equiv.) in DMF (1 mL) was added Cs2CO3 (49.71 mg, 0.15 mmol, 1.00 equiv.) at room temperature. The resulting mixture was stirred at 100° C. for 24 h. The resulting mixture was filtered and the filtrate was purified by preparative HPLC to give (16.77 mg, 29.0%). MS (ES, m / z): [MH] - =378.1.
[0321] Example 2 Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] Step 1: 3,3,4,4,7-Pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one [ka] To a stirred mixture of 3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol (320 mg, 1.22 mmol, 1.00 equiv.) in mixed solvent (DCM / CH3CN / H2O=3 mL / 3 mL / 4.50 mL), NaIO4 (1044.25 mg, 4.882 mmol, 4.00 equiv.) and RuCl3·H2O (13.76 mg, 0.061 mmol, 0.05 equiv.) were added at room temperature. The resulting mixture was stirred at room temperature for 6 h. The resulting mixture was diluted with water and extracted with DCM. The combined organic layer was washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (3:1) to give the title compound (250 mg, 77.5%) as a white solid. MS (ES, m / z): [MH] - =263.0.
[0322] Step 2: 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred mixture of 3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (200 mg, 0.757 mmol, 1.00 equiv.) and 3-fluoro-5-hydroxybenzonitrile (103.81 mg, 0.757 mmol, 1.0 equiv.) in DMF (3 mL) was added Cs2CO3 (246.69 mg, 0.76 mmol, 1.0 equiv.) at room temperature. The resulting mixture was stirred at room temperature for 16 h. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (3:1) to give the title compound (200 mg, 69.3%) as a white semi-solid. MS(ES,m / z):[MH] - =380.0.
[0323] Example 3 Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (40 mg, 0.105 mmol, 1.00 equiv) in MeOH (1 mL) was added NaBH4 (7.94 mg, 0.210 mmol, 2.0 equiv) at room temperature. The resulting mixture was stirred at room temperature for 3 h. The reaction was quenched with aqueous HCl (2.0 M) at room temperature to pH=7. The resulting mixture was concentrated under vacuum. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC eluted with PE / EtOAc (3:1) to give the title compound (40 mg, 99.5%) as a colorless oil. MS(ES,m / z):[MH] - =382.0.
[0324] Example 4 Synthesis of 3-fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [4] [ka] To a stirred solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (20 mg, 0.05 mmol, 1.00 equiv) in DCM (0.5 mL) was added DAST (6.73 mg, 0.04 mmol, 0.80 equiv) dropwise at -50 °C. The resulting mixture was stirred at -50 °C to -40 °C for 30 min. The reaction mixture was quenched with aqueous NaHCO3 and extracted with DCM. The organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title compound (4.3 mg, 21.3%) as a white solid. MS (ES, m / z): [MH] - =384.1.
[0325] Example 5 Synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (5) and 3-fluoro-5-(((1R,2aS)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (6) [ka] Step 1: (R)-1-Allyl-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol [ka] To a stirred solution of t-BuONa (21.6 mg, 0.225 mmol, 0.10 equiv) in toluene (3.0 mL) was added a solution of (S)-2-((3-(tert-butyl)-2-hydroxybenzyl)amino)-N,N,3-trimethylbutanamide (275.8 mg, 0.90 mmol, 0.40 equiv) in toluene (0.5 mL), followed by a solution of MeOH (90.2 mg, 2.8 mmol, 1.25 equiv) in toluene (0.5 mL), followed by a solution of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (0.50 g, 2.25 mmol, 1.00 equiv) in toluene (0.5 mL). After stirring at room temperature for 15 min, 4,4,5,5-tetramethyl-2-(prop-2-en-1-yl)-1,3,2-dioxaborolane (416.1 mg, 2.48 mmol, 1.10 equiv) in toluene (0.5 mL) was added slowly. The resulting mixture was stirred at 60° C. for 6.5 h, cooled, and diluted with ethyl acetate. After separation, the combined organic layers were washed with water and brine, and dried over Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with DCM / PE (0-40%) to give the title compound (0.52 g, 87.4%) as a pale yellow oil. MS (ES, m / z): [M-1] - =263.0.
[0326] Step 2: (1R)-7-Bromo-2,2,3,3,6-pentafluoro-1-(prop-2-en-1-yl)inden-1-ol [ka] To a stirred solution of (R)-1-allyl-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (5.0 g, 18.93 mmol, 1.00 equiv) in tetrahydrofuran (60 mL) was added 2.0 M LDA (28.4 mL, 56.8 mmol, 3.0 equiv) dropwise under nitrogen atmosphere at -40°C. After stirring at -40°C for 1 h, a solution of carbon tetrabromide (7.53 g, 22.71 mmol, 1.20 equiv) in THF was added dropwise at -40°C. The resulting mixture was stirred at -40°C for an additional 10 min and then quenched with 1.0 M aqueous HCl (100 mL) at -40°C. The resulting mixture was extracted with MTBE. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography, eluting with EtOAc / PE (0-30%) to give the crude product as a pale yellow oil. This crude product was further purified by reversed-phase C18 silica gel column (mobile phase, ACN in water, gradient 50%-95% in 12 min) to give the title compound (3.5 g, 53.9%) as a pale yellow oil. MS (ES, m / z): [M-1] - =340.9.
[0327] Step 3: (R)-3,3,4,4,7-Pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol [ka] To a stirred mixture of (R)-1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (3.50 g, 10.20 mmol, 1.00 equiv.) in DMF (5.0 mL) was added AcONa (2.51 g, 30.60 mmol, 3.00 equiv.) and Pd(dppf)Cl2·CH2Cl2 (0.83 g, 1.02 mmol, 0.10 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 100 °C under nitrogen atmosphere for 3 h, cooled, diluted with water, and then extracted with ethyl acetate. The combined organic layers were washed with water and brine, and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the title compound (2.0 g, 74.8%) as a pale yellow solid. MS(ES,m / z):[M-1] - =260.9.
[0328] Step 4: (R)-3,3,4,4,7-Pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one [ka] To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol (2.00 g, 7.63 mmol, 1.00 equiv.) in mixed solvent (DCM / MeCN / H2O=1 / 1 / 1.5, 70.0 mL) was added RuCl3·H2O (86.0 mg, 0.38 mmol, 0.05 equiv.) at room temperature. To the resulting mixture was added NaIO4 (6.53 g, 30.53 mmol, 4.0 equiv.) in portions at room temperature. After stirring at room temperature for 1 h, the reaction mixture was diluted with water and then extracted with DCM. The combined organic layer was washed with saturated aqueous Na2S2O3, water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated to give the crude title compound (1.85 g, 91.8%) as a pale yellow solid, which was used in the next step without further purification. MS (ES, m / z): [M-1] -=262.9.
[0329] Step 5: (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred solution of (R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (1.85 g, 7.0 mmol, 1.00 equiv.) and 3-fluoro-5-hydroxybenzonitrile (0.86 g, 6.30 mmol, 0.90 equiv.) in DMF (20.0 mL) was added Cs2CO3 (2.28 g, 7.00 mmol, 1.00 equiv.) at room temperature. After stirring at room temperature for 16 h, the reaction mixture was quenched with water at 0 °C and then extracted with EtOAc. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the title compound (1.95 g, 73.0%) as a white solid. MS(ES, m / z):[M-1]-=380.1.
[0330] Step 6: 3-Fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred solution of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (1.95 g, 5.12 mmol, 1.00 equiv) in MeOH (20.0 mL) was added NaBH4 (0.29 g, 7.67 mmol, 1.50 equiv) portionwise at room temperature. After stirring at room temperature for 3 h, the reaction mixture was quenched with 2.0 M aqueous HCl at 0 °C, diluted with water, and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the title compound (1.80 g, 91.8%) as a white solid. MS (ES, m / z): [M-1] - =382.0.
[0331] Step 7: 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred solution of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (384.8 mg, 1.04 mmol, 1.00 equiv) in DCM (5.0 mL) was added DAST (185.05 mg, 1.148 mmol, 1.10 equiv) dropwise at -50°C. The resulting mixture was stirred at -50°C for 30 min, then quenched with NaHCO3 (aq) and extracted with DCM. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluted with EtOAc / PE (0-40%) to give the crude product (~80% ee), which was purified by preparative CHIRAL-HPLC to give products 5 and 6 as white solids. 5: MS (ES, m / z): [M-1] - =384.1.t R :1.36 minutes; 6: MS (ES, m / z): [M-1] - =384.1.t R :1.54 minutes.
[0332] Instrument: Shimadzu LC-20AD; Column: CHIRALPAK IA-3, 50*4.6mm, 3um; Mobile phase A: n-hexane (0.1% TFA); Mobile phase B: ethanol; Flow rate: 1.0mL / min; Concentration of B phase: 20.0%.
[0333] Example 7 Synthesis of 3-fluoro-5-(((1R,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] Step 1: (1S,2aR)-7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl 4-nitrobenzoic acid [ka] To a stirred solution of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (150 mg, 0.39 mmol, 1.00 equiv.), 4-nitrobenzoic acid (131 mg, 0.78 mmol, 2.00 equiv.) and PPh3 (205 mg, 0.78 mmol, 2.00 equiv.) in THF (4.0 mL) was added DEAD (136 mg, 0.78 mmol, 2.00 equiv.) dropwise at 0° C. under a nitrogen atmosphere. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 2 h, then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (5 / 1) to give the title compound (160 mg, 76.8%) as a pale yellow solid. MS (ES, m / z): [MH] - =531.0.
[0334] Step 2: 3-Fluoro-5-(((1S,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred mixture of (1S,2aR)-7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl 4-nitrobenzoate (130 mg, 0.24 mmol, 1.00 equiv.), HO (0.4 mL) and THF (2.0 mL) was added LiOH·HO (15 mg, 0.36 mmol, 1.50 equiv.) at room temperature. The resulting mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was dissolved in water and the mixture was acidified to pH=5 with 1.0 M aqueous HCl. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with water and brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give the title compound (80 mg, 85.5%) as an off-white solid. MS(ES,m / z):[MH] - =382.0.
[0335] Step 3: 3-Fluoro-5-(((1R,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred solution of 3-fluoro-5-(((1S,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (50 mg, 0.13 mmol, 1.00 equiv) in DCM (2.0 mL) was added a solution of DAST (21 mg, 0.13 mmol, 1.00 equiv) in DCM (0.5 mL) dropwise at -50 °C. The resulting mixture was stirred at -40 to -50 °C for 30 min and then quenched with NaHCO3 (aq). The mixture was extracted with DCM and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by preparative HPLC to give the title compound (2.2 mg, 4.4%) as a white solid. MS(ES,m / z):[MH] - =384.1.
[0336] Example 8 Synthesis of 1,3,3,4,4-pentafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol [ka] Step 1: 3,3,4,4-tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one [ka] To a stirred mixture of 3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (95 mg, 0.36 mmol, 1.00 equiv.) and 5-fluoropyridin-3-ol (41 mg, 0.36 mmol, 1.00 equiv.) in DMF (2.00 mL) was added Cs2CO3 (128.90 mg, 0.40 mmol, 1.10 equiv.) at room temperature under nitrogen atmosphere. After stirring at room temperature for 4 h, the reaction mixture was quenched with water at 0° C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc=3 / 1) to give the title compound (85 mg, 66%) as a white solid. MS(ES,m / z):[M+1] + =358.1.
[0337] Step 2: 3,3,4,4-Tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta-[cd]indene-1,2a-diol [ka] To a stirred solution of 3,3,4,4-tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (85 mg, 0.24 mmol, 1.00 equiv.) in MeOH (1.50 mL) was added NaBH4 (18 mg, 0.48 mmol, 2.00 equiv.) at room temperature. After stirring at room temperature for 1 h, the reaction mixture was quenched with saturated aqueous NH4Cl solution at 0 °C. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (80 mg, 93.7%) as a pale yellow solid. MS (ES, m / z): [M+1] + =360.1.
[0338] Step 3: 1,3,3,4,4-Pentafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol [ka] To a stirred solution of 3,3,4,4-tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]indene-1,2a-diol (30 mg, 0.08 mmol, 1.00 equiv) in THF (1.00 mL) was added DAST (20 mg, 0.12 mmol, 1.50 equiv) at -50°C under nitrogen atmosphere. After stirring at -50 to -30°C for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 at 0°C. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give the title compound (3 mg, 10%) as a white solid. MS (ES, m / z): [M+1] + =362.1.
[0339] Example 9 Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydrospiro-[cyclopenta[cd]indene-1,1'-cyclopropane]-7-yl)oxy)benzonitrile [ka] To a stirred mixture of diethylzinc (0.53 mL, 0.53 mmol, 1.0 M in hexanes) in DCM (3 mL) was added TFA (60 mg, 0.526 mmol, 4.00 equiv) dropwise at 0° C. under nitrogen atmosphere. The resulting mixture was stirred at 0° C. for 10 min. To the above mixture was added CH2I2 (141 mg, 0.53 mmol, 4.0 equiv) dropwise at 0° C. The resulting mixture was stirred at 0° C. for an additional 10 min, followed by addition of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (50 mg, 0.132 mmol, 1.00 equiv). The reaction mixture was stirred at 0° C. for 10 min and then at room temperature for an additional 1 h. The reaction mixture was quenched with water and extracted with CH2Cl2. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (5.6 mg, 10.8%) as a white solid. MS (ES, m / z): [MH] - =392.1.
[0340] Example 10 Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred mixture of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (30 mg, 0.08 mmol, 1.00 equiv.) and phenyl sulfide (1.47 mg, 0.008 mmol, 0.10 equiv.) in ethyl acetate (3 mL) and CH3OH (3 mL) was added 10% Pd / C (20 mg) at room temperature. The resulting mixture was stirred at room temperature under a hydrogen atmosphere for 48 h and then filtered. The filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (9 mg, 30%) as a white solid. MS (ES, m / z): [MH] - =380.1.
[0341] Example 11 Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (20 mg, 0.05 mmol, 1.00 equiv.) in THF (0.60 mL) was added bromo(methyl)magnesium (1.0 M, 0.16 mL, 0.16 mmol, 3.05 equiv.) dropwise at −78° C. under nitrogen atmosphere. The resulting mixture was stirred at −78° C. for 1 h under nitrogen atmosphere and then quenched with saturated aqueous NH4Cl (2 mL) at −78° C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title compound (10 mg, 48.0%) as a white solid. MS(ES,m / z):[MH] - =396.2.
[0342] Example 12 Synthesis of 3-fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred mixture of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (30 mg, 0.07 mmol, 1.00 equiv.) in DCM (1.5 mL) was added DAST (12 mg, 0.07 mmol, 1.00 equiv.) dropwise at −50° C. under nitrogen atmosphere. The resulting mixture was stirred at −50 to −40° C. for 1.5 h under nitrogen atmosphere and then quenched with saturated aqueous NaHCO3 at 0° C. The resulting mixture was extracted with DCM and the combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (4.3 mg, 14.3%) as a white solid. MS (ES, m / z): [MH] - =398.1.
[0343] Example 13 Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] Step 1: O-(7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl) 1H-imidazole-1-carbothioate [ka] To a stirred solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (100 mg, 0.26 mmol, 1.00 equiv.) and DMAP (6 mg, 0.05 mmol, 0.20 equiv.) in DCE (2.0 mL) was added di(1H-imidazol-1-yl)methanethione (56 mg, 0.31 mmol, 1.20 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 3 h. The reaction mixture was concentrated and the residue was purified by preparative TLC (PE / EtOAc 2:1) to give the title compound (80 mg, 62%). MS (ES, m / z): [M+H] + =494.1.
[0344] Step 2: 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred solution of O-(7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl)1H-imidazole-1-carbothioate (65 mg, 0.13 mmol, 1.00 equiv.) and Bu3SnH (115 mg, 0.40 mmol, 3.00 equiv.) in toluene (2.0 mL) was added AIBN (65 mg, 0.40 mmol, 3.00 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 50° C. for 16 h, cooled, diluted with water, and extracted with EtOAc. The combined organic layer was washed with water and brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by preparative TLC (PE / EtOAc=2 / 1) and preparative HPLC to give the title compound (12 mg, 25%) as a white solid. MS (ES, m / z): [MH] - =366.2.
[0345] Example 14 Synthesis of 3-((2a-amino-1,3,3,4,4-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile [ka] Step 1: N-(7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfinamide [ka] To a stirred mixture of 7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (1.00 g, 3.32 mmol, 1.00 equiv) and 2-methylpropane-2-sulfinamide (0.81 g, 6.64 mmol, 2.00 equiv) in THF (20.0 mL) was added Ti(OEt)4 (3.03 g, 13.29 mmol, 4.00 equiv) at room temperature. After stirring at 75 °C for 4 h, the reaction mixture was cooled and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (900 mg, 67.0%) as a brown oil. MS (ES, m / z): [M+1] + =404.0.
[0346] Step 2: N-(1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide [ka] To a stirred solution of N-(7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfinamide (900 mg, 2.23 mmol, 1.00 equiv) in THF (15.0 mL) was added allylmagnesium bromide (2.0 M, 1.34 mL, 2.70 mmol, 1.20 equiv) at 0° C. After stirring at 0° C. for 1.5 h, the reaction mixture was quenched with saturated aqueous NH4Cl solution at 0° C. and then extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-50%) to give the title compound (750 mg, 75.5%) as a pale yellow oil. MS (ES, m / z): [M+1] + =446.1.
[0347] Step 3: 2-Methyl-N-(3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]-inden-2a-yl)propane-2-sulfinamide [ka] To a stirred mixture of N-(1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (750 mg, 1.68 mmol, 1.00 equiv.) and Pd(dppf)Cl2·CH2Cl2 (137 mg, 0.17 mmol, 0.10 equiv.) in DMF (15.0 mL) was added NaOAc (414 mg, 5.05 mmol, 3.00 equiv.) at room temperature under nitrogen atmosphere. After stirring at 100 °C for 1.5 h, the reaction mixture was cooled to room temperature, quenched with water, and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (10%-40%) to give the title compound (450 mg, 73.3%) as a pale yellow solid. MS (ES, m / z): [M+1]+ =366.1.
[0348] Step 4: 3,3,4,4,7-Pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-amine [ka] To a stirred solution of 2-methyl-N-(3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-yl)propane-2-sulfinamide (150 mg, 0.41 mmol, 1.00 equiv) in 1,4-dioxane (1.0 mL) was added a solution of HCl in 1,4-dioxane (4.0 M, 1.00 mL, 4.0 mmol, 9.74 equiv) at room temperature. After stirring at room temperature for 5 h, the reaction mixture was quenched with aqueous NaHCO3 at room temperature and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (85 mg, 79.3%) as a pale yellow oil. MS(ES,m / z):[M+1] + =262.1.
[0349] Step 5: 2a-Amino-3,3,4,4,7-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one [ka] To a stirred mixture of 3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-amine (85 mg, 0.325 mmol, 1.00 equiv) and NaIO4 (278 mg, 1.30 mmol, 4.00 equiv) in CH3CN (0.50 mL) and DCM (0.50 mL) was added water (0.75 mL) and RuCl3·H2O (7.34 mg, 0.03 mmol, 0.10 equiv) at room temperature. After stirring at room temperature for 1 h, the resulting mixture was diluted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by preparative TLC (PE / EtOAc=3 / 1) to give the title compound (45 mg, 52.5%) as a pale yellow oil. MS(ES,m / z):[M-1] - =261.9.
[0350] Step 6: 3-((2a-amino-3,3,4,4-tetrafluoro-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile [ka] To a stirred mixture of 2a-amino-3,3,4,4,7-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (40 mg, 0.15 mmol, 1.00 equiv.) and 3-fluoro-5-hydroxybenzonitrile (21 mg, 0.15 mmol, 1.00 equiv.) in DMF (1.00 mL) was added Cs2CO3 (50 mg, 0.15 mmol, 1.00 equiv.) at room temperature. After stirring at room temperature for 1.5 h, the reaction was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc=3 / 1) to give the title compound (35 mg, 60.3%) as a white solid. MS (ES, m / z): [M+1] + =381.1.
[0351] Step 7: 3-((2a-amino-3,3,4,4-tetrafluoro-1-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile [ka] To a stirred solution of 3-((2a-amino-3,3,4,4-tetrafluoro-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile (35 mg, 0.09 mmol, 1.00 equiv) in MeOH (0.50 mL) was added NaBH4 (5 mg, 0.13 mmol, 1.4 equiv) at room temperature. After stirring at room temperature for 0.5 h, the reaction mixture was quenched with saturated aqueous NH4Cl solution at 0 °C and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (30 mg, 85.3%) as a pale yellow oil. MS (ES, m / z): [M+1] + =383.1.
[0352] Step 8: 3-((2a-amino-1,3,3,4,4-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile [ka] To a stirred solution of 3-((2a-amino-3,3,4,4-tetrafluoro-1-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile (25 mg, 0.07 mmol, 1.00 equiv) in DCM (1.0 mL) was added DAST (16 mg, 0.10 mmol, 1.5 equiv) at room temperature. After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 at 0° C. and extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative HPLC to give the title compound (6 mg, 24%) as a white solid. MS (ES, m / z): [M+1] + =385.1.
[0353] Example 15 Synthesis of 3-fluoro-5-((1,1,2a,3,3,4,4-heptafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] To a stirred mixture of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (30 mg, 0.08 mmol, 1.00 equiv.) in DCM (1.0 mL) was added 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride (59 mg, 0.24 mmol, 3.00 equiv.) and hydrogen fluoride pyridine (0.05 mL, 65%-70%) at room temperature. The resulting mixture was stirred at room temperature under nitrogen atmosphere for 24 h, then diluted with water and extracted with DCM. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative HPLC to give the title compound (9.9 mg, 31.1%) as a white solid. MS (ES, m / z): [MH] - =404.1.
[0354] Example 16 Synthesis of 3-((3,3-difluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile [ka] Step 1: 3-Fluoro-5-((7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile [ka] A 2 L round bottom flask was charged with 3-fluoro-5-((1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile (28 g, 104.77 mmol, 1.00 equiv), F-TEDA-BF4 (33 g, 93.15 mmol, 0.89 equiv) and CH3CN (840 mL). To this stirred solution was added a solution of I2 (24 g, 94.56 mmol, 0.90 equiv) in CH3CN (560 mL) dropwise at 60 °C. The resulting mixture was stirred at 60 °C for 3 h. The mixture was cooled to room temperature and then concentrated under vacuum. To the residue was added ethyl acetate (250 mL) and the resulting mixture was stirred at 80 °C for 1 h. The mixture was cooled to room temperature and the precipitated solid was collected by filtration and washed with Et2O to give the titrated compound (16.8 g, 40.8%) as an off-white solid. MS (ES, m / z): [M+H] + =394.0.
[0355] Step 2: 3-((2,2-difluoro-7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile [ka] To a stirred mixture of 3-fluoro-5-((7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-benzonitrile (3.600 g, 9.15 mmol, 1.00 equiv.) and butan-1-amine (6.7 g, 91.57 mmol, 10.00 equiv.) in toluene (90 mL) was added TFA (209 mg, 1.83 mmol, 0.20 equiv.) dropwise at room temperature. The resulting mixture was stirred at 100° C. under nitrogen atmosphere for 16 h and then concentrated under vacuum. The residue was dissolved in CH3CN (90 mL) followed by the addition of Na2SO4 (5.2 g, 36.62 mmol, 4.00 equiv.) and F-TEDA-BF4 (6.5 g, 18.31 mmol, 2.00 equiv.) at room temperature. The resulting mixture was stirred at 80° C. for 2 h, diluted with water and extracted with EtOAc. The combined organic layers were washed with water, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (10:1) to give (1.60 g, 40.7%) of the title compound as a yellow solid.
[0356] Step 3: 3-((1-allyl-2,2-difluoro-1-hydroxy-7-iodo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile [ka] To a stirred mixture of 3-((2,2-difluoro-7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (449 mg, 1.05 mmol, 1.00 equiv.) and allyl bromide (253.15 mg, 2.093 mmol, 2.00 equiv.) in THF (10 mL) was added pyridine (165.52 mg, 2.09 mmol, 2.00 equiv.) and (1S,2R)-2-amino-1,2-diphenylethanol (446.30 mg, 2.09 mmol, 2.00 equiv.) at room temperature. Indium powder (240.26 mg, 2.09 mmol, 2.00 equiv.) was then added to the solution and the resulting mixture was stirred at room temperature under a nitrogen atmosphere for 8 h. The resulting mixture was filtered and the filter cake was washed with EtOAc. The filtrate was concentrated and purified by silica gel column chromatography eluting with PE / EtOAc (9:1) to give the titrated compound (430 mg, 87.2%) as a yellow oil. MS (ES, m / z): [MH] - =470.0.
[0357] Step 4: 3-((3,3-difluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile [ka] To a stirred solution of 3-((1-allyl-2,2-difluoro-1-hydroxy-7-iodo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (430 mg, 0.91 mmol, 1.00 equiv.) and NaOAc (225 mg, 2.74 mmol, 3.00 equiv.) in DMF (10 mL) was added Pd(dppf)Cl2·CHCl2 (75 mg, 0.09 mmol, 0.10 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 100 °C under nitrogen atmosphere for 3 h and then filtered. The filter cake was washed with EtOAc, and the filtrate was washed with H2O, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (223 mg, 71.2%) as a yellow oil.
[0358] Example 17 Synthesis of 3-((3,3-difluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile [ka] In a 25 mL two-neck round bottom flask, 3-((3,3-difluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (210 mg, 0.61 mmol, 1.00 equiv), DCM (2.0 mL), MeCN (2.0 mL) and H2O (3.0 mL) were added at room temperature. Then, RuCl3·H2O (7 mg, 0.03 mmol, 0.05 equiv) was added to the solution. To the above mixture, NaIO4 (523 mg, 2.45 mmol, 4.00 equiv) was added in portions over 2 min at room temperature, and the resulting mixture was stirred at room temperature for 3 h. The resulting mixture was extracted with DCM and the combined organic layer was washed with aqueous Na2S2O3, H2O, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc (5:1) to give the titrated compound (107 mg, 50.7%) as a yellow oil. MS (ES, m / z): [2M-H] - =689.1.
[0359] Example 18 Synthesis of 3-((3,3-difluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile [ka] In an 8 mL sealed tube, 3-((3,3-difluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (100 mg, 0.29 mmol, 1.00 equiv) and MeOH (2.00 mL) were added at room temperature. To the above mixture, NaBH4 (22 mg, 0.58 mmol, 2.0 equiv) was added portionwise at 0 °C, and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water at 0 °C and neutralized to pH = 7 with aqueous HCl (1.0 M). The resulting mixture was extracted with DCM, and the combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative TLC (PE / EtOAc = 5 / 1) to give the titrated compound (78 mg, 77.6%) as a white solid.
[0360] Example 19 Synthesis of 3-fluoro-5-((1,3,3-trifluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile [ka] To a stirred solution of 3-((3,3-difluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydrofuran-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (20 mg, 0.06 mmol, 1.00 equiv) in THF (0.50 mL) was added a solution of DAST (9.35 mg, 0.06 mmol, 1.00 equiv) in DCM (0.2 mL) dropwise at −50° C. under nitrogen atmosphere. The resulting mixture was stirred at −50° C. for 1 h under nitrogen atmosphere and then quenched with water at −40° C. The mixture was neutralized to pH=7 with saturated aqueous NaHCO3 solution and then extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative HPLC to give the title compound (5.7 mg, 28.3%) as a white solid. MS(ES,m / z):[2M-H] - =697.2.
[0361] Example 20 Synthesis of 3-fluoro-5-((1,1,2,2,3,3,4-heptafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile [ka] Step 1: Ethyl 2,2-difluoro-2-(2,2,3,3,6-pentafluoro-1-hydroxy-2,3-dihydro-1H-inden-1-yl)acetate [ka] A mixture of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (10.0 g, 45.02 mmol, 1.00 equiv), In (7.7 g, 67.06 mmol, 1.5 equiv) and ethyl 2-bromo-2,2-difluoroacetate (13.7 g, 67.5 mmol, 1.50 equiv) in THF (150 mL) was stirred at 60° C. for 16 h under N2 atmosphere. The reaction was quenched with aqueous HCl (2.0 M, 50 mL) at room temperature and the resulting mixture was extracted with ethyl acetate. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EA (5 / 1) to give the title compound (8.0 g, 51.3%) as a pale yellow oil. MS (ES, m / z): [M-1] - =345.0
[0362] Step 2: 1,1,2,2,3,3,5-heptafluoro-2a-hydroxy-1,2,2a,3-tetrahydro-4H-cyclopenta[cd]inden-4-one [ka] To a stirred solution of ethyl 2,2-difluoro-2-(2,2,3,3,6-pentafluoro-1-hydroxy-2,3-dihydro-1H-inden-1-yl)acetate (500 mg, 1.44 mmol, 1.00 equiv) in THF (10 mL) was added LDA (2.2 mL, 4.40 mmol, 2.0 M, 3.06 equiv) dropwise at −78° C. under N2 atmosphere. The resulting mixture was stirred at −78° C. for 1 h and then quenched with saturated aqueous NH4Cl solution (10 mL) at −78° C. The resulting mixture was extracted with ethyl acetate and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with PE / EA (3 / 1) to give the crude product. The crude product was purified by preparative HPLC to give the title product (34 mg, 7.8%) as a pale yellow oil. MS(ES,m / z):[M-1] - =298.9
[0363] Step 3: 3-Fluoro-5-((1,1,2,2,3,3-hexafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile [ka] A mixture of 1,1,2,2,3,3,5-heptafluoro-2a-hydroxy-1,2,2a,3-tetrahydro-4H-cyclopenta-[cd]inden-4-one (100 mg, 0.33 mmol, 1.00 equiv.), Cs2CO3 (217 mg, 0.67 mmol, 2.00 equiv.) and 3-fluoro-5-hydroxybenzonitrile (50 mg, 0.36 mmol, 1.10 equiv.) in DMF (2 mL) was stirred at -10 °C under N2 atmosphere for 1 h. The crude reaction mixture was used directly in the next step without further purification. MS (ES, m / z): [M-1] - =416.0.
[0364] Step 4: 3-Fluoro-5-((1,1,2,2,3,3-hexafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile [ka] To a stirred solution of crude 3-fluoro-5-((1,1,2,2,3,3-hexafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (0.33 mmol, 1.00 equiv.) in MeOH (2 mL) was added NaBH4 (25 mg, 0.66 mmol, 2.00 equiv.) portionwise at -10 °C under N2 atmosphere. The resulting mixture was stirred at -10 °C for 1 h and then quenched with saturated aqueous NH4Cl solution. The resulting mixture was extracted with ethyl acetate and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3 / 1) to give the title compound (90 mg, 63.6%) as a pale yellow oil in two steps. MS(ES,m / z):[M-1] - =418.0.
[0365] Step 5: 3-Fluoro-5-((1,1,2,2,3,3,4-heptafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile [ka] To a stirred solution of 3-fluoro-5-((1,1,2,2,3,3-hexafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (50 mg, 0.12 mmol, 1.00 equiv.) in DCM (1.0 mL) was added DAST (38 mg, 0.24 mmol, 2.00 equiv.) dropwise at −20° C. under N2 atmosphere. The resulting mixture was stirred at room temperature for 2 h and quenched with saturated aqueous NaHCO3. The resulting mixture was extracted with DCM and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (14 mg, 27.5%) as a pale yellow solid. MS (ES, m / z): [M-1] - =420.0.
[0366] Example 21 Synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile [ka] Step 1: (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-2,2-d2)oxy)benzonitrile [ka] To a stirred mixture of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (3.0 g, 7.87 mmol, 1.00 equiv) in THF (60 mL) was added dropwise a solution of NaOD (645 mg, 15.737 mmol, 2.00 equiv) in DO (24 mL) at room temperature. The resulting mixture was stirred at room temperature for 4 h, then diluted with DO and extracted with MTBE. The combined organic layers were dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with PE / EA (3:1) to give the title compound (2.3 g, 76.3%) as a white solid. MS (ES, m / z): [MH] - =382.1.
[0367] Step 2: 3-Fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile [ka] To a stirred mixture of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-2,2-d2)oxy)benzonitrile (1.5 g, 3.883 mmol, 1.00 equiv.) in CD3OD (15 mL) was added NaBD4 (329 mg, 7.827 mmol, 2.00 equiv.) at 5° C. The resulting mixture was stirred at room temperature for 2 h and then quenched with D2O at room temperature. The resulting mixture was extracted with MTBE and the combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluted with PE / EA (3:1) to give the title compound (1.5 g, 99.2%) as a pale yellow solid. MS (ES, m / z): [MH] - =385.1.
[0368] Step 3: 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile [ka] To a stirred mixture of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile (1.5 g, 3.88 mmol, 1.00 equiv.) in THF (21 mL) was added DBU (1.18 g, 7.77 mmol, 2.00 equiv.) and pyridine-2-sulfonyl fluoride (814 mg, 5.05 mmol, 1.30 equiv.) in THF (2 mL) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature under nitrogen atmosphere for 16 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (4:1). The resulting product was further purified by chiral preparative HPLC to give the optically pure title compound (740 mg, 49.1%) as a white solid. MS (ES, m / z): [MH] - =387.1.
[0369] Example 22 Synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3 [ka] Step 1: 3-Bromo-5-fluorophen-2,4,6-d3-ol [ka] 3-Bromo-5-fluorophenol (5.00 g, 26.18 mmol, 1.00 equiv) and 60% D2SO4 (13.09 g, 78.53 mmol, 3.00 equiv) in D2O were added to a 40 mL sealed tube at room temperature. The resulting mixture was stirred at 75 °C for 18 h and then slowly poured onto ice. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with water, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the product. The product was added to 60% D2SO4 in D2O and the above procedure was repeated four more times to give the title compound (4.20 g, 82.7% yield) as a yellow oil. MS (ES, m / z): [MH] - =191.9.
[0370] Step 2: 3-Fluoro-5-hydroxybenzonitrile-2,4,6-d3 [ka] To a stirred solution of 3-bromo-5-fluorophen-2,4,6-d3-ol (100 mg, 0.515 mmol, 1.00 equiv.) and Zn(CN)2 (121 mg, 1.03 mmol, 2.0 equiv.) in DMF (2.0 mL) was added Pd(PPh3)4 (60 mg, 0.05 mmol, 0.10 equiv.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 100° C. for 3 h under nitrogen atmosphere and then quenched with water at room temperature. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with water, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give the title compound (37 mg, 51.2%) as a white solid. MS (ES, m / z): [MH] - =139.0.
[0371] Step 3: (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile-2,4,6-d3 [ka] To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (179 mg, 0.68 mmol, 1.00 equiv.) and 3-fluoro-5-hydroxybenzonitrile-2,4,6-d3 (95 mg, 0.68 mmol, 1.00 equiv.) in DMF (3.5 mL) was added Cs2CO3 (221 mg, 0.68 mmol, 1.00 equiv.) at room temperature. After stirring at room temperature for 16 h, the reaction mixture was quenched with water at 0 °C. The resulting mixture was extracted with EtOAc and the combined organic layers were washed with H2O, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the titrated compound (170 mg, 65.3%) as a white solid. MS (ES, m / z): [MH] - =383.0.
[0372] Step 4: 3-Fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3 [ka] To a stirred mixture of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile-2,4,6-d3 (170 mg, 0.442 mmol, 1.00 equiv.) in CD3OD (3.5 mL) was added NaBD4 (37 mg, 0.885 mmol, 2.00 equiv.) portionwise at room temperature. The resulting mixture was stirred at room temperature for 3 h, diluted with D2O (3.0 mL), and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-40%) to give the titrated compound (120 mg, 70.0%) as a white solid. MS (ES, m / z): [2M-H] - =773.1.
[0373] Step 5: 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3 [ka] To a stirred mixture of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3 (125 mg, 0.32 mmol, 1.00 equiv.) in THF (1.6 mL) was added DBU (98 mg, 0.65 mmol, 2.00) and pyridine-2-sulfonyl fluoride (68 mg, 0.42 mmol, 1.30 equiv.) in THF (0.4 mL) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature under nitrogen atmosphere for 16 h. The reaction solution was purified by silica gel column chromatography, eluted with PE / EtOAc (4:1), followed by preparative HPLC purification to give the titrated compound (10 mg, 8.0%) as a white solid. MS(ES,m / z):[MH]- =388.1.
[0374] Example 23 Synthesis of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [23a] and (S)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [23b] [ka] To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol (400 mg, 1.53 mmol, 1.0 equiv, ca. 80% ee) and 3-fluoro-5-hydroxybenzonitrile (209 mg, 1.53 mmol, 1.0 equiv) in DMF (10 mL) was added Cs2CO3 (497 mg, 1.53 mmol, 1.0 equiv) at room temperature and the resulting mixture was stirred at 100° C. for 24 h. After the reaction mixture was cooled to room temperature, it was filtered. The filtrate was purified by preparative HPLC to give 131 mg of product as a mixture of enantiomers. The enantiomers were separated by chiral preparative HPLC [Column: CHIRALPAK OD-3, 50* 4.6mm, 3um OD30CC-QE001, flow rate: 1.0mL / min; oven temperature: 25°C; mobile phase A: n-hexane; mobile phase B: ethanol; concentration of B phase: 10%) to give 23a (65mg, 11.2%). MS (ES,m / z): [MH] - =378.0.tR:1.34min and 23b(6mg,1.0%);MS(ES,m / z):[MH] - =378.0.tR:1.77 minutes
[0375] Example 24 Synthesis of 3-fluoro-5-(((2aS,3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [24a] and 3-fluoro-5-(((2aS,3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [24b] [ka] Step 1: (R)-3-((4-(butylimino)-1,1,2,2-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile [ka] A solution of (R)-3-fluoro-5-((1,1,2,2-tetrafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (700 mg, 1.84 mmol, 1.0 equiv, ca. 80% ee), TFA (42 mg, 0.37 mmol, 0.2 equiv) and butylamine (1343 mg, 18.36 mmol, 10.0 equiv) in toluene (15 mL) was stirred at 100° C. for 16 h under a N2 atmosphere. The resulting mixture was concentrated in vacuo to give the title compound (1.0 g, crude) as a light brown oil, which was used directly in the next step. MS (ES, m / z): [M+1] + =437.2.
[0376] Step 2: 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile and 3-fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile [ka] A mixture of (R)-3-((4-(butylimino)-1,1,2,2-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (1.0 g crude, 1.84 mmol, 1.0 equiv.), sodium sulfate (651 mg, 4.58 mmol, 2.5 equiv.) and Selectfluor (1.05 g, 2.96 mmol, 1.6 equiv.) in MeCN (15 mL) was stirred at 60° C. for 4 h under N2 atmosphere. The crude product was purified by preparative HPLC to give 150 mg of one isomer and 300 mg of the other isomer. MS (ES, m / z): [M-1] - =397.9.
[0377] Step 3: 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile and 3-fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile [ka] 3-Fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-Fluoro-5-(((2aS,3 R )-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile and 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile, respectively, as shown below. or 3-Fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile.
[0378] To a stirred solution of 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (1.0 equiv.) in MeOH was added NaBH4 (2.0 equiv.) in portions at 0° C. under N2 atmosphere. The resulting mixture was stirred at room temperature for 1 h and quenched with saturated aqueous NH4Cl solution. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile, respectively, as a pale yellow oil. MS (ES, m / z): [2M-1] - =801.2.
[0379] Step 4: 3-fluoro-5-(((2aS,3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [ka] 3-Fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-Fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile was converted to 3-fluoro-5-(((2aS,3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile as follows.
[0380] To a stirred solution of 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (1.0 equiv.) in DCM was added DAST (1.5 equiv.) dropwise at −40° C. under N2 atmosphere. The resulting mixture was stirred at −40° C. for 2 h and quenched with saturated aqueous NH4Cl solution. The resulting mixture was extracted with DCM. The combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give 3-fluoro-5-(((2aS,3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile as a light yellow solid, respectively. MS (ES, m / z): [M-1] - =402.0.
[0381] The stereochemistry at *C of compounds 24a and 24b has not been determined, so compound 24a is either compound 24a1 or 24a2. [ka]
[0382] Similarly, compound 24b is compound 24b1 or 24b2. [ka]
[0383] Example 25 Synthesis and polymorphic characterization of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (compound 5) [ka] A 3000 mL three-neck round-bottom flask was charged with 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrahydrofuran-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (350 g, 0.762 mol, 1.0 equiv.) in THF (3.5 L) at room temperature and DBU (232.1 g, 1.53 mol, 2.0 equiv.). To this solution was added dropwise a solution of pyridine-2-sulfonyl fluoride (159.7 g, 0.991 mmol, 1.3 equiv.) in THF (700 mL) at 10-15 °C. The resulting mixture was stirred at room temperature for 12 h and then diluted with water and EtOAc. The suspension was filtered through silica gel and the phases were separated. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with water and brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1 to 7 / 1) to give the crude product (400 g) as an off-white solid. The crude product was separated by SFC (column: DAICEL CHIRALPAK AS (250 mm * 50 mm, 10 um) to give 250 g of crude product. Heptane (1.0 L) was added to the crude product, and the mixture was stirred at 40 °C for 2 hours. The mixture was filtered to give the pure title product (230 g). SFC conditions: Column: Chiralpak AD-3 50 x 4.6 mm ID, 3 μm Mobile phase: Phase A, CO2; Phase B, EtOH (0.05% DEA) Gradient elution: 5% to 40% B in A; Flow rate: 3 mL / min Column temperature: 35°C; back pressure: 100 bar; t R :0.904 minutes.
[0384] Characterization of polymorphs: Compound 5 (15.5 mg) was added to 0.4 mL of a mixture of n-pentanol / heptane (9:1) at 50° C. After stirring the mixture for 3 days, the solid was collected by filtration to obtain crystalline form A. XRPD patterns were acquired on an X-ray diffractometer (Bruker D8 Advance) using an incident beam of Cu Kα (1.5418 Å) from a generator operated at 40 kV and 40 mA. The system was equipped with a LynxEye detector. A sample of compound 5 was scanned from 3 to 40° 2θ with a step size of 0.02° 2θ. The data was analyzed using DIFFRAC plus Evaluation Package Release 2010. The XRPD spectrum of crystalline form A is shown in FIG. 1. The peak list of the XRPD spectrum, with the diffraction angles (2θ) reported in degrees, is shown in Table A below.
[0385] [Table 10]
[0386] [Table 11]
[0387] Crystallization of Compound 5 under the following conditions also afforded Form A.
[0388] Method A Compound 5 (15 mg / ml) was dissolved in MeOH, IPA, MTBE, EtOAc, IPAc or toluene and the solution was evaporated at room temperature to give compound 5 as a crystalline solid. XRPD analysis showed that the crystalline solid was Form A.
[0389] Method B Compound 5 (approximately 10 mg) was added to 0.5 mL of antisolvent at 50° C., and then a solvent was added to dissolve the solid, as shown in Table B below. The mixture was filtered, and the solution was slowly cooled to room temperature and stirred at room temperature for 1 day. The crystals were filtered and XRPD analysis was performed.
[0390] [Table 12]
[0391] Method C Compound 5 was dissolved in a solvent and an anti-solvent was added with stirring at room temperature, 50° C. or an ice bath as indicated in Table C below. The crystallized solid was filtered and characterized by XRPD.
[0392] [Table 13]
[0393] Method D Compound 5 (about 10 mg) was dissolved in the solvent, and then the resulting solution was added to 0.5 mL of anti-solvent. The mixture was kept stirring at room temperature for 1 day, and the crystalline solid was analyzed by XRPD. The results are shown in Table D below.
[0394] [Table 14]
[0395] Biological Examples Example 1 VEGF ELISA assay The ability of the disclosed compounds to inhibit HIF-2α was measured by determining VEGF expression in 786-O cells. Approximately 7500 786-O cells were seeded into each well of a 96-well white clear bottom plate (07-200-566, Fisher Scientific) containing 200ul of growth medium. After 4 hours, compounds were dispensed into the wells by a Tecan D300e digital dispenser, with a starting concentration of 10uM and a 1 / 2 log dilution to a final concentration of 1nM. Each concentration was treated in duplicate. After approximately 20 hours, the medium was removed and fresh medium was added, followed by compound treatment as described above. After 24 hours, the cell culture medium was collected and VEGF concentration was determined using an ELISA kit (R&D systems, catalog number DVE00) according to the manufacturer's instructions.
[0396] EC 50 is calculated by GraphPad Prism using the dose-response inhibition (4-parameter) equation. Plates with cells were then subjected to a CellTiter-Glo Luminescent Cell Viability Assay (Promega) to determine the effect of these compounds on cell numbers after the above treatments.
[0397] [Table 15]
[0398] Formulation examples The following are representative formulations containing the compounds of the present disclosure.
[0399] Tablet formulation The following ingredients are mixed and pressed into a single scored tablet:
[0400] [Table 16]
[0401] Capsule formulation The following ingredients are blended and loaded into a hard shell gelatin capsule:
[0402] [Table 17]
[0403] Injectable preparations A compound of the disclosure (e.g., a compound of Formula I) in an appropriate amount of DI water containing 2% HPMC, 1% Tween 80 to at least 20 mg / mL.
[0404] Inhalation composition To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, suitable for inhalation administration.
[0405] Topical gel compositions To prepare a pharmaceutical topical gel composition, 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropylcellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate, and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into a container, such as a tube, suitable for topical administration.
[0406] Ophthalmic solution composition To prepare pharmaceutical eye drop composition, 100mg of compound disclosed herein is mixed with 0.9g of NaCl in 100mL of purified water, and filtered using a 0.2 micron filter.The resulting isotonic solution is then incorporated into an ophthalmic delivery unit, such as an eye dropper, suitable for ophthalmic administration.
[0407] Nasal spray solution To prepare a medicinal nasal spray solution, 10 g of a compound disclosed herein is mixed with 30 mL of 0.05 M phosphate buffer (pH 4.4). The solution is placed into a nasal applicator designed to deliver 100 ul of spray for each administration.
Claims
1. Formula (I): 【Chemistry 1】 (In the formula, X 1 is CH or N; R 1 is hydroxy or amino; R 2 is hydrogen, deuterium, alkyl, or haloalkyl; R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy, or alkoxy; R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or R 5 and R 6 together with the carbon to which they are attached form an oxo, or an alkyldienyl; R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl, or haloalkoxy; L is O; R 8 R is aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl, where aryl or heteroaryl, each by itself or as part of an aralkyl or heteroaralkyl, or heterocyclyl by itself or as part of a heterocyclylalkyl, is independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidenyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. a , R b and R c is substituted with; R 9 R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, alkylsulfonyl, or heteroaryl, wherein said heteroaryl is independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, and cyano. d , R e and R f optionally substituted with; or R 9 and R 2 are attached to the same carbon atom, they can combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene. or a pharma- ceutically acceptable salt thereof.
2. R 3 and R 4 is independently halo, or R 3 is halo, and R 4 is hydrogen, 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.
3. R 1 is hydroxy or amino, or a pharma- ceutically acceptable salt thereof.
4. X 1 is CR 7 The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt thereof.
5. Formula (IIa) or (IIb): 【Chemistry 2】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
6. Formula (IIa') or (IIb'): 【Chemistry 3】 2. The compound of claim 1 having the structure: or a pharma- ceutically acceptable salt thereof.
7. R 3 is fluoro, R 4 The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.
8. R 3 and R 4 The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof, wherein is fluoro.
9. The compound according to any one of claims 1 to 8, wherein L is O, or a pharma- ceutically acceptable salt thereof.
10. R 8 is phenyl substituted with R a , R b and R c , and R a , R b and R c are independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocyclyl, or a pharma- ceutically acceptable salt thereof.
11. R 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl or 3-cyano-5-difluoromethylphenyl, the compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof.
12. R 8 is heteroaryl substituted with R a , R b and R c , and R a , R b and R c are independently selected from hydrogen, alkyl, haloalkyl, haloalkyloxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted heterocyclyl, or a pharma- ceutically acceptable salt thereof.
13. R 2 is hydrogen, methyl or ethyl, and R 9 The compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen, alkyl, halo, hydroxy or alkoxy.
14. Formula (VIIIa) or (VIIIb): 【Chemistry 4】 The compound according to any one of claims 6 and 10 to 13, having the structure: or a pharma- ceutically acceptable salt thereof.
15. R 2 is hydrogen, and R 9 15. The compound of claim 14, having the structure of formula (VIIIb), or a pharma- ceutically acceptable salt thereof, wherein is hydrogen, fluoro, or methyl.
16. 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile; 3-fluoro-5-(((1R,2aS)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-fluoro-5-(((1R,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 1,3,3,4,4-pentafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol; 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydrospiro[cyclopenta[cd]-indene-1,1′-cyclopropane]-7-yl)oxy)benzonitrile; 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-((2a-amino-1,3,3,4,4-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile; (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; (S)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; and 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 2. The compound of claim 1, selected from:
17. 3-fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile, having the following structure: 【Chemistry 5】 2. The compound of claim 1 selected from the following: and pharma- ceutically acceptable salts thereof.
18. It is 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile, having the following structure: 【Chemistry 6】 compound.
19. 20. The crystalline form A polymorph of the compound of claim 18, having an X-ray powder diffraction pattern comprising peaks at angular positions 11.4, 12.9, 15.8, 18.6 and 20.1, said angular positions may vary by ±0.2 degrees 2θ as measured by X-ray powder diffraction using an X-ray wavelength of 1.5418 Å.
20. 20. The crystalline form A polymorph of claim 19, wherein the X-ray powder diffraction pattern of said form A polymorph comprises peaks at angular positions 10.1, 11.4, 12.9, 15.8, 18.6 and 20.1, said angular positions may vary by ±0.2 degrees 2θ.
21. 20. The crystalline form A polymorph of claim 19, wherein the X-ray powder diffraction pattern of said form A polymorph comprises peaks at angular positions 10.1, 11.4, 12.9, 15.8, 18.6, 20.1 and 21.7, said angular positions may vary by ±0.2 degrees 2θ.
22. 20. The crystalline form A polymorph of claim 19, wherein the X-ray powder diffraction pattern of said form A polymorph comprises peaks at angular positions 10.1, 11.4, 12.9, 15.8, 18.6, 19.6, 20.1 and 21.7, said angular positions may vary by ±0.2° θ.
23. 23. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof or a compound according to claim 18, or comprising the crystalline form A polymorph according to any one of claims 19 to 22, and a pharma- ceutically acceptable excipient.
24. 26. Use of a compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof or a compound according to claim 18 or the crystalline form A polymorph according to any one of claims 19 to 22 in the manufacture of a medicament for treating cancer, inflammatory disease, liver disease, iron overload or pulmonary disease in a patient.
25. 25. The use according to claim 24, wherein the disease is cancer and the compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof, or the compound according to claim 18, or the crystalline form A polymorph according to any one of claims 19 to 22, may optionally be used in combination with at least one other anti-cancer agent.
26. 26. The use according to claim 24 or 25, wherein the disease is a cancer selected from renal cancer, glioblastoma, neuroblastoma, paraganglioma, pheochromocytoma, pancreatic neuroendocrine tumor, liver cancer, colorectal cancer, somatostatinoma, hemangioblastoma, gastrointestinal stromal tumor, pituitary tumor, leiomyoma, leiomyosarcoma, multiple cell carcinoma, retinal cancer, von Hippel-Lindau disease, astrocytoma, lung cancer, non-small cell lung cancer, melanoma, breast cancer, cervical cancer, head and neck cancer, ovarian cancer, prostate cancer, esophageal squamous cell carcinoma, and uterine leiomyoma.
27. 27. The use of claim 26, wherein the cancer is clear cell renal cell carcinoma, VHL disease, or hepatocellular carcinoma.
28. 28. The use of any one of claims 24 to 27, wherein the at least one other anticancer agent is selected from the group consisting of sunitinib, sorafenib, regorafiniib, lenvatinib, vandetanib, carbozantinib, axitinib, aflibercept, bevacizumab, pazopanib, rapamycin (sirolimus), temsirolimus, everolimus, XL388, XL765, AZD2013, PF04691502, PKI-587, BEZ235, GDC0349 (atezolizumab), MEDI4736 (durvalumab), abemaciclib, palbociclib, and ribociclib.
Citation Information
Patent Citations
Polymorphs of compounds as prolyl hydroxylase inhibitors, and their use
JP2014524920A
Aryl ethers and their uses
JP2016534134A
Tricyclic inhibitors of HIF-2-alpha and uses thereof
US20160362390A1
Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2016168510A1
Novel compounds, uses and methods for their preparation
WO2018031680A1
